Tag: multidisciplinary

[ad_2]

Source link

  • Directive giant upconversion by supercritical bound states in the continuum

    [ad_1]

    Theory

    In the section ‘TCMT: critical coupling for an isolated mode’, the local field enhancement at critical coupling for an isolated resonant mode is demonstrated. In the section ‘Open-resonator TCMT’, the non-Hermitian Hamiltonian formalism of TCMT for FW-BIC formation is used. It will be shown that, as the asymptotic condition of BIC cannot be ideally reached, the FW quasi-BIC originates from non-orthogonal modes. This understanding will then be used in the section ‘Supercritical coupling’ to evaluate the coupling between the dark FW quasi-BIC and the bright leaky partner, demonstrating the analogy to EIT and the equation for supercritical local field enhancement. In the section ‘RCWA validation’, we validate the TCMT results using RCWA.

    TCMT: critical coupling for an isolated mode

    The basic equation describing the evolution of the mode amplitude A1 (oscillator 1) in a resonating system with a characteristic angular frequency ω1 = 2πc/λ1, is

    $$\frac{{\rm{d}}{A}_{1}}{{\rm{d}}t}=\,j{\omega }_{1}{A}_{1}-\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{r}}}}\right){A}_{1},$$

    (2)

    in which energy can be lost through absorption (or other additive non-radiative channels, such as scattering by dielectric fluctuations or in-plane leakage) with decay rate γa = 1/τa, as well as through direct far-field coupling with external radiation in the outer space with a decay rate γr = 1/τr. The amplitude is normalized such that |A1|2 represents the energy of the mode15. When adding the driving field of power |s+|2 and monochromatic time dependence exp(int), associated with the external excitation and coupled with the resonator with coefficient κi, the equation becomes

    $$\frac{{\rm{d}}{A}_{1}}{{\rm{d}}t}=\,j{\omega }_{1}{A}_{1}-\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{r}}}}\right){A}_{1}+{\kappa }_{{\rm{i}}}\,{s}_{+}.$$

    (3)

    The solution is

    $${A}_{1}({\omega }_{{\rm{in}}})=\frac{{\kappa }_{{\rm{i}}}\,{s}_{+}}{j({\omega }_{{\rm{in}}}-{\omega }_{1})+\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{r}}}}\right)}.$$

    (4)

    It is possible to demonstrate that the input power coupling must be related to the radiation decay as \({\kappa }_{{\rm{i}}}=\sqrt{2/{\tau }_{{\rm{r}}}}\) by invoking energy conservation and time-reversal symmetry of Maxwell’s equations. On resonance, that is, when the input frequency 2πc/λin = ωin is set at the peak ω1, it follows that

    $${A}_{1}({\omega }_{1})=\frac{\sqrt{2/{\tau }_{{\rm{r}}}}{s}_{+}}{1/{\tau }_{{\rm{a}}}+1/{\tau }_{{\rm{r}}}}.$$

    (5)

    Now let us consider that the quality factor Q of a resonator is defined as the ratio between the stored (W) and the lost energy fractions. Indeed, for the absorption-related power loss Pabs (or, more generally, all non-radiative losses) and the radiation loss Prad, the following holds true

    $$\frac{1}{Q}=\frac{1}{{Q}_{{\rm{a}}}}+\frac{1}{{Q}_{{\rm{r}}}}=\frac{{P}_{{\rm{abs}}}}{{\omega }_{1}W}+\frac{{P}_{{\rm{rad}}}}{{\omega }_{1}W}=\frac{2}{{\omega }_{1}}\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{r}}}}\right)=\frac{2}{{\omega }_{1}}\left({\gamma }_{{\rm{a}}}+{\gamma }_{{\rm{r}}}\right).$$

    (6)

    The driving field has amplitude Ei = s+/Ac, in which Ac is a normalized cross-section, which we define as Ac = 1, for simplicity. The local field of the resonant mode has amplitude given by \({E}_{{\rm{loc}}}={A}_{1}/\sqrt{{V}_{{\rm{eff}}}}\), with Veff the normalized effective mode volume. Thus, from equation (5), it follows that the local field enhancement G is given by

    $$G=\frac{| {E}_{{\rm{loc}}}{| }^{2}}{| {E}_{{\rm{i}}}{| }^{2}}\simeq \frac{{Q}^{2}}{{Q}_{{\rm{r}}}{V}_{{\rm{eff}}}}=\frac{{Q}_{{\rm{a}}}^{2}{Q}_{{\rm{r}}}^{2}}{{Q}_{{\rm{r}}}{({Q}_{{\rm{r}}}+{Q}_{{\rm{a}}})}^{2}{V}_{{\rm{eff}}}},$$

    (7)

    and depends on the ratio between the total quality factor Q = 1/(1/Qa + 1/Qr) = QaQr/(Qa + Qr) and the radiation quality factor Qr. Clearly, if QrQa as for the ideal BIC with Qr → ∞, then asymptotically \(G\approx {Q}_{{\rm{a}}}^{2}/{Q}_{{\rm{r}}}\to 0\). The maximum enhancement Gcr is reached when Qr = Qa, at the critical coupling condition, for which

    $${G}_{{\rm{cr}}}\approx \frac{{Q}_{{\rm{a}}}^{4}}{{Q}_{{\rm{a}}}^{3}{V}_{{\rm{eff}}}}=\frac{{Q}_{{\rm{a}}}}{{V}_{{\rm{eff}}}}.$$

    (8)

    The above result has been applied to BICs in several papers13 and its origin dates to the general theory of optical and electrical resonators discussed in textbooks15. Supposing a nearly ideal resonator with Qr = Qa, the maximum field enhancement would reach the physical capacity limit imposed by the unavoidable system losses represented by Qa. In dielectric resonators sustaining quasi-BICs, the critical coupling point can be approached by breaking the in-plane symmetry of the system to tune the radiation quality factor that scales quadratically with the asymmetry parameter5, which requires precise nanostructure engineering and knowledge of the system losses.

    Open-resonator TCMT

    The theory of FW-BIC formation owing to coupling of two leaky modes has been reviewed in ref. 47. The demonstration based on the non-Hermitian Hamiltonian of temporal coupled modes can be found in recent papers19. The formation of FW-BICs has gained attention particularly in the context of photonic-crystal slabs with vertical asymmetry, in which TM-like and TE-like modes couple and interfere48,49. However, it is worth noting that the existence of non-radiating modes arising from the interference of vector TE-like and TM-like eigenmodes was first discussed in ref. 17. It was found that, in 2D holey textured slabs, TE and TM modes can couple at virtually any point in the first Brillouin zone, leading to anticrossing of their dispersion and formation of a mode with zero imaginary part of its eigenfrequency, known as an FW-BIC2. In this study, a photonic-crystal slab placed over a dielectric waveguide substrate with air cladding was considered, breaking vertical symmetry and favouring the coupling of vector TE-like and TM-like modes. The same system was used in our previous work10, in which we experimentally observed and applied the FW quasi-BIC, and it is also used in the present study.

    To develop what we term the ‘supercritical enhancement equation’, we start from the non-Hermitian Hamiltonian of coupled waves25,48. By generalizing equation (3), the dynamic equations for resonance amplitudes can be written in the following form

    $$\frac{{\rm{d}}{\bf{A}}}{{\rm{d}}t}=(\,j\hat{\varOmega }-{\hat{\varGamma }}_{{\rm{r}}}-{\hat{\varGamma }}_{{\rm{a}}}){\bf{A}}+{\hat{K}}_{{\rm{i}}}^{{\rm{T}}}{{\bf{s}}}^{+},$$

    (9)

    $${{\bf{s}}}^{-}=\hat{C}{{\bf{s}}}^{+}+\hat{D}{\bf{A}},$$

    (10)

    in which both \(\hat{\varOmega }\) and \({\hat{\varGamma }}_{{\rm{r}}}\) matrices are Hermitian matrices representing the resonance frequencies and the radiation decay, respectively. On the other hand, \({\hat{\varGamma }}_{{\rm{a}}}\) represents non-radiative losses and is initially set to zero \({\hat{\varGamma }}_{{\rm{a}}}=0\) to isolate the radiative rate associated with an ideal BIC. The resonant mode is excited by the incoming far-field waves s+ coupled to the resonator with coefficients denoted by \({\hat{K}}_{{\rm{i}}}\). The outgoing waves s depend on the direct scattering channel \(\hat{C}\) and the resonant modes A by means of the decay port coefficients in \(\hat{D}\). Energy conservation and time-reversal symmetry imply that \({\hat{K}}_{{\rm{i}}}=\hat{D}\) and that the coupling with the port is linked with radiation loss, implying that \({\hat{D}}^{\dagger }\hat{D}=2{\hat{\varGamma }}_{{\rm{r}}}\). These relationships determine the elements of \({\hat{K}}_{{\rm{i}}}^{{\rm{T}}}\) and imply that \({\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}({\hat{\varGamma }}_{{\rm{r}}})={\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}({\hat{D}}^{\dagger }\hat{D})={\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}(\hat{D})\). Also, \(\hat{D}=-\,\hat{C}\,{\hat{D}}^{\star }\). Let us consider a system denoted by A = (A1, A2)T, in which A1 and A2 represent the amplitudes of two modes with frequencies ω1 and ω2, respectively. These resonances have radiative lifetimes τr1 = 1/γr1 and τr2 = 1/γr2. Moreover, both resonances may experience absorption loss, characterized by 1/τa = γa. It is important to note that, for the specific case of the avoided crossing point, the absorption terms for both modes are the same, as we demonstrate below. Then, in general, γ1,2 = γr1,r2 + γa, but for now, let’s turn γa = 0.

    Recall that the modes of the resonator are defined as the eigenmodes of the non-Hermitian Hamiltonian operator \(\hat{H}=j\hat{\varOmega }-{\hat{\varGamma }}_{{\rm{r}}}\) (neglecting non-radiative loss). Only Hermitian matrices allow for a diagonal representation with orthogonal eigenvectors, whereas non-Hermitian matrices may have linearly dependent or linearly independent but non-orthogonal eigenvectors, or they may have orthogonal eigenvectors depending on specific properties such as parity–time symmetry. The Hamiltonian and its eigenvalues are functions of the in-plane momentum k = ko(sinθcosϕ, sinθsinϕ). A previous study demonstrated that the eigenvectors of the non-Hermitian Hamiltonian are always non-orthogonal when the total number of independent decay ports is less than the number of optical modes and both modes are coupled to the decay ports25. The crucial concept here is that of independent decay ports, which are related to the sharing of the vertical symmetry of the modes. In the case of evolving TE-like and TM-like modes, the inversion of their character at the avoided crossing can occur at any point in energy–momentum space. We know that the eigenmodes of a matrix form an orthogonal basis if and only if \({\hat{H}}^{\dagger }\hat{H}=\hat{H}{\hat{H}}^{\dagger }\). Because both \(\hat{\varOmega }\) and \({\hat{\varGamma }}_{{\rm{r}}}\) are Hermitian, this is equivalent to the relation \(\hat{\varOmega }\,{\hat{\varGamma }}_{{\rm{r}}}={\hat{\varGamma }}_{{\rm{r}}}\,\hat{\varOmega }\), which implies that \(\hat{\varOmega }\) and \({\hat{\varGamma }}_{{\rm{r}}}\) can be simultaneously diagonalized. When considering two eigenmodes and a single independent radiation channel, in which \({\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}({\hat{\varGamma }}_{{\rm{r}}})=1\), one of the orthogonal eigenmodes of the matrix will have a pure imaginary eigenvalue. This indicates that one of the two modes has an infinite lifetime (BIC) and does not couple to the decay port. As a non-zero coupling with the single decay port exists, the two eigenvectors in the resonator system will always be non-orthogonal25. Therefore, the modes are generally non-orthogonal if a single radiation channel is involved. However, they can satisfy the orthogonality condition at a specific point in momentum space. This point is referred to as an ideal FW-BIC point kBIC when the Hamiltonian (\(\hat{H}=j\hat{\varOmega }-{\hat{\varGamma }}_{{\rm{r}}}\), defined below) has a purely imaginary eigenvalue (or, equivalently, \(\hat{\varOmega }+j{\hat{\varGamma }}_{{\rm{r}}}\) has a purely real eigenvalue). This allows for the simultaneous diagonalization of the Hermitian matrices \(\hat{\varOmega }\) and \({\hat{\varGamma }}_{{\rm{r}}}\).

    FW condition

    The Hamiltonian of a two-waves-two-ports system is represented as:

    $$\hat{H}=j(\begin{array}{cc}{\omega }_{1} & \kappa \\ \kappa & {\omega }_{2}\end{array})-(\begin{array}{cc}{\gamma }_{{\rm{r}}1} & X\\ {X}^{\star } & {\gamma }_{{\rm{r}}2}\end{array})=j(\begin{array}{cc}{\omega }_{1}+j{\gamma }_{{\rm{r}}1} & \kappa +jX\\ \kappa +j{X}^{\star } & {\omega }_{2}+j{\gamma }_{{\rm{r}}2}\end{array})\equiv j(\begin{array}{cc}{\mathop{\omega }\limits^{ \sim }}_{1} & {\mathop{\omega }\limits^{ \sim }}_{12}\\ {\mathop{\omega }\limits^{ \sim }}_{21} & {\mathop{\omega }\limits^{ \sim }}_{2}\end{array}),$$

    (11)

    in which κ measures the near-field coupling and X represents the coupling mediated by the continuum between the two closed, uncoupled channel resonances of frequencies ω1 and ω2. Following the calculation in refs. 19,25, X can be expressed as

    $$X=\sqrt{{\gamma }_{{\rm{r1}}}{\gamma }_{{\rm{r2}}}}{{\rm{e}}}^{j\psi },$$

    (12)

    in which the phase angle ψ describes the relative phase of the coupling with the open channel and in general with the two ports (up and down). The eigenvalues of the two diagonal frequency and decay matrices of the Hamiltonian at the BIC point, defined by

    $$\hat{{H}^{{\rm{r}}}}({{\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})=\hat{\varOmega }+j{\hat{\varGamma }}_{{\rm{r}}}=(\begin{array}{cc}{\mathop{\omega }\limits^{ \sim }}_{+} & 0\\ 0 & {\mathop{\omega }\limits^{ \sim }}_{-}\end{array})+j(\begin{array}{cc}{\mathop{\gamma }\limits^{ \sim }}_{+} & 0\\ 0 & {\mathop{\gamma }\limits^{ \sim }}_{-}\end{array}),$$

    (13)

    and associated with the collective modes \({\widetilde{A}}_{+},{\widetilde{{\rm{A}}}}_{-}\), are related to the uncoupled mode frequency and decay rates by

    $${\mathop{\omega }\limits^{ \sim }}_{\pm }+{j\mathop{\gamma }\limits^{ \sim }}_{\pm }=({\omega }_{1}+{\omega }_{2})/2+j({\gamma }_{{\rm{r}}1}+{\gamma }_{{\rm{r}}2})/2\,+$$

    (14)

    $$\pm \frac{1}{2}\sqrt{{\left[({\omega }_{1}-{\omega }_{2})+j({\gamma }_{{\rm{r}}1}-{\gamma }_{{\rm{r}}2})\right]}^{2}+4{\left(\kappa +j\sqrt{{\gamma }_{{\rm{r}}1}{\gamma }_{{\rm{r}}2}}{{\rm{e}}}^{j\psi }\right)}^{2}}.$$

    (15)

    This relation allows us to determine the asymptotic FW condition as a function of the uncoupled mode frequency, the decay rate and the coupling rate among closed channel modes κ

    $$\kappa ({\gamma }_{{\rm{r}}1}-{\gamma }_{{\rm{r}}2})=\sqrt{{\gamma }_{{\rm{r}}1}{\gamma }_{{\rm{r}}2}}{{\rm{e}}}^{j\psi }({\omega }_{1}-{\omega }_{2}),$$

    (16)

    $$\psi =m{\rm{\pi }},\,m\in {\mathscr{Z}}$$

    (17)

    Substituting (γr1 − γr2) from equation (16) into equation (15), it is possible to find that the third term with the square root is exactly equal to the second term in equation (14) and cancels, or adds with it, depending on the sign ±. The dark mode acquires ideally zero radiation loss (say, \({\widetilde{\omega }}_{-}\) without loss of generality). At this condition, the eigenvalues are

    $${\mathop{\omega }\limits^{ \sim }}_{+}{+j\mathop{\gamma }\limits^{ \sim }}_{+}=\frac{{\omega }_{1}+{\omega }_{2}}{2}+\frac{\kappa ({\gamma }_{{\rm{r}}1}+{\gamma }_{{\rm{r}}2})}{2\sqrt{{\gamma }_{{\rm{r}}1}{\gamma }_{{\rm{r}}2}}{{\rm{e}}}^{j\psi }}+\,j({\gamma }_{{\rm{r}}1}+{\gamma }_{{\rm{r}}2}),$$

    (18)

    $${\mathop{\omega }\limits^{ \sim }}_{-}+\,j{\mathop{\gamma }\limits^{ \sim }}_{-}=\frac{{\omega }_{1}+{\omega }_{2}}{2}-\frac{\kappa ({\gamma }_{{\rm{r}}1}+{\gamma }_{{\rm{r}}2})}{2\sqrt{{\gamma }_{{\rm{r}}1}{\gamma }_{{\rm{r}}2}}{{\rm{e}}}^{j\psi }},\,\,\,{\rm{w}}{\rm{i}}{\rm{t}}{\rm{h}}\,{\mathop{\gamma }\limits^{ \sim }}_{-}=0,$$

    (19)

    in which the wave of amplitude \({\widetilde{A}}_{-}\) has no radiative loss and becomes the ideal FW-BIC (ideally dark mode), whereas all radiative loss is transferred to the bright mode \({\widetilde{A}}_{+}\). At this point in momentum space (k = kBIC), \(\hat{\varOmega }\) and \({\hat{\varGamma }}_{{\rm{r}}}\) are both diagonal, and because \({\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}({\hat{\varGamma }}_{{\rm{r}}})=1\) (only a single independent decay port exists), the resonant states interfere to annihilate the coupling with the radiation channel of the BIC mode, which guarantees energy conservation, as any coupling among the final orthogonal modes asymptotically vanishes47.

    However, arbitrarily close to the BIC point in the momentum, both modes experience non-zero radiative loss. The modes are coupled with a single independent radiation channel and, thus, are non-orthogonal because their coupling guarantees energy conservation. This behaviour holds true in any real system, particularly with momentum close to ideal FW-BICs, referred to as FW quasi-BICs. It is worth mentioning that, in the presence of non-negligible absorption loss, the modes are always non-orthogonal. If we perturb the ideal FW-BIC condition by moving in momentum space, in the representation in which \(\hat{\varOmega }\) is diagonal, in general, \({\hat{\Gamma }}_{r}\) must have non-zero off-diagonal terms to ensure energy conservation, or similarly, in the representation in which \({\hat{\varGamma }}_{{\rm{r}}}\) is diagonal, \(\hat{\varOmega }\) must have non-zero off-diagonal terms, κ12,21, which represent the near-field coupling. This is a key concept that implies that \(\forall {\bf{k}}:{\bf{k}}\simeq {{\bf{k}}}_{{\rm{BIC}}}\), the new perturbed Hamiltonian \(\hat{{H}^{{\rm{r}}}}({\bf{k}}\simeq {{\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})\) for the final coupled modes, the FW quasi-BIC \({A}_{-}({\bf{k}}\simeq {{\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})\) and bright \({A}_{+}({\bf{k}}\simeq {{\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})\) modes, can be represented with non-zero off-diagonal terms in \(\hat{\varOmega }({\bf{k}}\simeq {{\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})\), when \({\hat{\varGamma }}_{{\rm{r}}}\) is diagonal because of energy conservation, as described below (Extended Data Fig. 1a).

    The same non-Hermitian Hamiltonian can also describe the effect of coupled-resonance-induced transparency resulting from the interference of non-orthogonal eigenvectors, that is, at a wavevector different from the ideal FW-BIC condition. Hsu et al. demonstrated that, when several resonances (two or more) are connected to a single independent decay port, a transparency window, known as coupled-resonance-induced transparency, always occurs regardless of the radiation loss values of the resonances because of the off-diagonal terms21. Therefore, this coupling, also necessary for any FW quasi-BIC point, can give rise to coupled-resonance-induced transparency in special cases. The condition for EIT can, in principle, also occur with momentum near the ideal FW-BIC point, for example, when kEIT = kBIC + δk (Extended Data Fig. 1a). At the EIT point, the slow light condition increases the photon–matter interaction time, enhancing emission properties.

    Supercritical coupling

    Coupled-resonance-induced transparency in far-field representation

    We first describe the occurrence of the transparency condition in the far-field representation and its link with the near-field representation. We then consider the perturbation of the Hamiltonian close to the FW-BIC to explicitly demonstrate that the FW quasi-BIC, despite being a quasi-dark mode, can reach the maximum physical limit of the local field enhancement under the supercritical coupling condition, thanks to the near-field coupling with its bright partner. The calculations presented here follow refs. 21,25 for clarity of description, but with harmonic time dependence convention exp(int). Let us first restate the TCMT problem by writing the dynamical equations for the two modes that are non-orthogonal in the representation in which \(\hat{\varOmega }({\bf{k}})\) is diagonal, with a single radiation channel. Because the representation is changed with respect to equation (11), we consider different symbols for elements in the matrices and we adopt this representation only because the condition for EIT emergence is rather simple to show:

    $$\frac{{\rm{d}}}{{\rm{d}}t}\left(\begin{array}{c}{A}_{1}\\ {A}_{2}\end{array}\right)=\left[j\left(\begin{array}{cc}{\bar{\omega }}_{1} & 0\\ 0 & {\bar{\omega }}_{2}\end{array}\right)-\left(\begin{array}{cc}{\bar{\gamma }}_{{\rm{r}}1} & {\gamma }_{12}\\ {\gamma }_{12} & {\bar{\gamma }}_{{\rm{r}}2}\end{array}\right)-\left(\begin{array}{cc}{\gamma }_{{\rm{a}}} & 0\\ 0 & {\gamma }_{{\rm{a}}}\end{array}\right)\right]\left(\begin{array}{c}{A}_{1}\\ {A}_{2}\end{array}\right)+\left(\begin{array}{c}{d}_{1}\\ {d}_{2}\end{array}\right){s}^{+},$$

    (20)

    $${s}^{-}={c}_{21}{s}^{+}+{d}_{1}{A}_{1}+{d}_{2}{A}_{2}.$$

    (21)

    In equation (20), the off-diagonal terms γ12 in the radiative decay matrix must be non-zero for energy conservation if both modes decay in the channel, meaning that the decay matrix and the frequency matrix cannot have diagonal forms simultaneously21,25. In equation (21), s is the transmitted wave and we have, owing to the presence of the substrate-breaking vertical symmetry, that the direct scattering matrix elements are c11 = −c22 = (1 − n)/(1 + n), with n index of the substrate and \({c}_{12}={c}_{21}=2\sqrt{n}/(1+n)\). Equation (21) simplifies when the system is mirror symmetric because n = 1 (ref. 21). Invoking again energy conservation and time-reversal symmetry and using the relations between \({\hat{\varGamma }}_{{\rm{r}}}\), \(\hat{C}\) and \(\hat{D}\):

    $${d}_{1,2}=j\sqrt{2{\bar{\gamma }}_{{\rm{r}}1,{\rm{r}}2}/(n+1)},$$

    (22)

    $${\gamma }_{12}=\sqrt{{\bar{\gamma }}_{{\rm{r}}1}{\bar{\gamma }}_{{\rm{r}}2}}.$$

    (23)

    Let us keep using a mirror-symmetric system to determine the condition of induced transparency. The experimental case is then calculated with RCWA, showing that the condition for induced transparency also holds for vertical asymmetry. The complex transmission coefficient at regime is25

    $$t={{\rm{c}}}_{21}\mp \frac{({c}_{11}\pm {c}_{12})[\,j({\omega }_{{\rm{in}}}-{\bar{\omega }}_{2})+{\gamma }_{{\rm{a}}}]{\bar{\gamma }}_{{\rm{r}}1}+[\,j({\omega }_{{\rm{in}}}-{\bar{\omega }}_{1})+{\gamma }_{{\rm{a}}}]{\bar{\gamma }}_{{\rm{r}}2}}{[\,j({\omega }_{{\rm{in}}}-{\bar{\omega }}_{1})+{\gamma }_{{\rm{a}}}+{\bar{\gamma }}_{{\rm{r}}1}][\,j({\omega }_{{\rm{in}}}-{\bar{\omega }}_{2})+{\gamma }_{{\rm{a}}}+{\bar{\gamma }}_{{\rm{r}}2}]-{\bar{\gamma }}_{{\rm{r}}1}{\bar{\gamma }}_{{\rm{r}}2}},$$

    (24)

    in which |c11 + c12| = |c22 − c12| and we have already established that absorption is the same for both modes and given by γa. The top (bottom) signs are used when both modes are even (odd) with respect to vertical symmetry. In the limit \({\gamma }_{{\rm{a}}}\ll {({\bar{\omega }}_{1}-{\bar{\omega }}_{2})}^{2}/\max ({\bar{\gamma }}_{{\rm{r}}1},{\bar{\gamma }}_{{\rm{r}}2})\), the absorptive decay rate is sufficiently small that the transmission coefficient approaches 1 (EIT condition) when the numerator of the second term becomes zero at the transparency frequency ωt, given by

    $${\omega }_{{\rm{in}}}=\frac{{\bar{\omega }}_{1}{\bar{\gamma }}_{{\rm{r}}2}+{\bar{\omega }}_{2}{\bar{\gamma }}_{{\rm{r}}1}}{{\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2}}\doteq {\omega }_{{\rm{t}}}.$$

    (25)

    This condition is always fulfilled when \({\bar{\omega }}_{1} < {\omega }_{{\rm{in}}} < {\bar{\omega }}_{2}\) provided that the resonances are sufficiently close, regardless of their radiative damping. In a real system for γa ≠ 0, the approximation to this condition is a consequence of the optical theorem, for which t cannot reach ideally 1. Nonetheless, the fast dispersion induced at the transparency frequency leads to an enhancement of the local optical field50,51,52. Indeed, when the EIT is approached, light is substantially slowed down, which favours light–matter interactions and enhances the optical-emission process. With this simple demonstration, we have proved that FW-BIC and EIT can be close in principle in the momentum space. Indeed, the induced transparency arises from the coupling of two optical modes to the same radiation channel, which is also the same framework near FW-BIC.

    Near-field representation

    Although the diagonal frequency matrix representation is useful for finding the transparency condition, the next one will provide more insight into the mode coupling. Let us now rewrite the dynamic equations (20) in the representation in which the radiative decay is diagonal. We will indicate the final eigenvector waves at k = kEIT with amplitudes A+ and A (not to be confused with the amplitudes \({\widetilde{A}}_{+},{\widetilde{{\rm{A}}}}_{-}\) at the FW-BIC wavevector k = kBIC in equation (13). As mentioned earlier, \({\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}({\hat{\varGamma }}_{{\rm{r}}})={\rm{r}}{\rm{a}}{\rm{n}}{\rm{k}}(\hat{D})=1\). Thus, in its diagonal representation, \({\hat{\varGamma }}_{{\rm{r}}}\) has only one non-trivial element because the determinant must be zero. It is straightforward to demonstrate that, in this equivalent representation (with c21 = 1),

    $$\frac{{\rm{d}}}{{\rm{d}}t}\left(\begin{array}{c}{{A}^{{\prime} }}_{+}\\ {{A}^{{\prime} }}_{-}\end{array}\right)=\left[j\left(\begin{array}{cc}{{\omega }^{{\prime} }}_{+} & {{\kappa }^{{\prime} }}_{12}\\ {{\kappa }^{{\prime} }}_{12} & {{\omega }^{{\prime} }}_{-}\end{array}\right)-\left(\begin{array}{cc}{{\gamma }^{{\prime} }}_{+} & 0\\ 0 & 0\end{array}\right)-\left(\begin{array}{cc}{{\gamma }^{{\prime} }}_{{\rm{a}}} & {{\zeta }^{{\prime} }}_{12}\\ {{\zeta }^{{\prime} }}_{21} & {{\gamma }^{{\prime} }}_{{\rm{a}}}\end{array}\right)\right]\left(\begin{array}{c}{{A}^{{\prime} }}_{+}\\ {{A}^{{\prime} }}_{-}\end{array}\right)+\left(\begin{array}{c}{{d}^{{\prime} }}_{1}\\ 0\end{array}\right){s}^{+},$$

    (26)

    $${s}^{-}={s}^{+}+{{d}^{{\prime} }}_{1}\,{{A}^{{\prime} }}_{+},$$

    (27)

    in which the connection with the previous representation of the diagonal frequency matrix is given by:

    $${{\omega }^{{\prime} }}_{+}=\frac{{\bar{\omega }}_{1}{\bar{\gamma }}_{{\rm{r}}1}+{\bar{\omega }}_{2}{\bar{\gamma }}_{{\rm{r}}2}}{{\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2}},$$

    (28)

    $${{\omega }^{{\prime} }}_{-}=\frac{{\bar{\omega }}_{1}{\bar{\gamma }}_{{\rm{r}}2}+{\bar{\omega }}_{2}{\bar{\gamma }}_{{\rm{r}}1}}{{\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2}},$$

    (29)

    $${{\kappa }^{{\prime} }}_{12}=\frac{({\bar{\omega }}_{2}-{\bar{\omega }}_{1})\sqrt{{\bar{\gamma }}_{{\rm{r}}1}{\bar{\gamma }}_{{\rm{r}}2}}}{{\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2}},$$

    (30)

    $${{\gamma }^{{\prime} }}_{+}={\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2},$$

    (31)

    $${{\gamma }^{{\prime} }}_{-}=0,$$

    (32)

    $${d}_{1}^{{\prime} }=\sqrt{{d}_{1}^{2}+{d}_{2}^{2}}.$$

    (33)

    The above relations are useful because they directly state that the transparency frequency ωt = ω, that is, it corresponds to the final dark mode. This link is important: at the transparency frequency, the fast dispersion slows down the light and enhances the local field, which corresponds to the dark mode. Although in the previous representation we were dealing with non-orthogonal modes in which their coupling was expressed in the far field, in this second representation, we can see that a non-radiative dark mode with γ = 0 is coupled by means of a non-zero near-field constant κ12 to a bright leaky wave with a decay rate \({{\gamma }^{{\prime} }}_{+}={\bar{\gamma }}_{{\rm{r}}1}+{\bar{\gamma }}_{{\rm{r}}2}\). These identities must not be confused with equations (18) and (19) that express the relations between the diagonal dark and bright modes at the FW-BIC point k = kBIC with the original uncoupled modes. Instead, the above equations refer to two different representations of the same modes at fixed and same wavevector k = kEIT ≠ kBIC. Here, when the drive field is turned off, the dark-mode amplitude decays to zero. In the linear regime, exchange energy occurs between the modes. We see below that, while the drive field is on, energy flows from the bright mode to the dark mode. As the drive field is turned off, energy flows from the dark mode to the bright mode. Consequently, the dark mode undergoes decay in the far field owing to its nearly zero direct coupling with the radiation channel and its non-zero near-field coupling with the bright mode53. In this alternative representation, it is the near-field coupling between a dark mode and the bright mode that gives rise to the transparency condition. This formulation aligns with the general framework used in the subradiant–superradiant model, which illustrates the analogue of EIT in photonic and plasmonic systems50,51,52.

    Maximum enhancement at the FW quasi-BIC

    The FW-BIC and classical analogue of EIT formalisms are derived from the same original framework of modes coupled to a single radiation channel: the EIT with non-zero off-diagonal terms, whereas the ideal FW-BIC is a limit of this framework with zero off-diagonal terms. Because the EIT occurs at the avoided crossing, FW-BIC must not be at the avoided crossing, which implies that the radiative decay rates of the closed channel modes in equation (16) differ, γr1 ≠ γr2. Thus, the ideal FW-BIC is not at the avoided crossing (ω1 = ω2) but is shifted in its vicinity. Both conditions can be fulfilled, in principle, for close wavevectors when, for example, γr1 5γr2 (see the simulated linewidths when the modes do not cross each other in Extended Data Fig. 3; orientation angle of the photonic crystal ϕ = 45°). This also means that the realization of EIT is possible when the involved dark mode is a perturbation of the FW-BIC mode, that is, it exhibits characteristics of an FW quasi-BIC. Although this will be shown using RCWA in our system, let us now explore the consequences for enhancing the local optical field.

    As shown in the scheme of Extended Data Fig. 1a, let us write explicitly the dynamical equations (13) and add the perturbation of the diagonal representation (FW-BIC point) of the Hamiltonian as we move away from the ideal BIC wavevector towards the EIT point. Because the radiative Q factor of a BIC scales as |k − kBIC|α with α ≥ 2, for any wavevector close to the BIC point, k = kBIC + ΔqkBIC, it is necessary to admit a finite non-zero decay rate of the dark mode A, that is, 1/γ = τR1 with γ → ε 0 and, as such, it is necessary to include a non-zero mode coupling κ12 ≠ 0 to guarantee energy conservation, as both modes are coupled to a single independent radiation channel. The perturbed Hamiltonian is \(\hat{{H}^{{\rm{r}}}}({{\bf{k}}\simeq {\bf{k}}}_{{\rm{B}}{\rm{I}}{\rm{C}}})=(\begin{array}{cc}{\omega }_{+} & {\kappa }_{12}\\ {\kappa }_{12} & {\omega }_{-}\end{array})+j(\begin{array}{cc}{\gamma }_{+} & 0\\ 0 & {\gamma }_{-}\end{array})\). It is important to note that the modes are the final coupled modes: their frequencies are considered shifted with respect to the exact frequencies of bright and dark modes of the FW point k = kBIC in equation (14). The finite decay rate of the dark mode turns it into a quasi-dark mode (FW quasiBIC), and this non-zero coupling to the radiation channel \((\sqrt{2{\gamma }_{-}}=\sqrt{2/{\tau }_{{\rm{R}}1}})\) will imply non-zero near-field (κ12) or far-field (γ12) coupling with the shifted bright partner, depending on the representation used. The bright mode has amplitude A+, with a decay rate 1/γ+ = τR2τR1. Generally, the off-diagonal terms can be kept complex to include both near-field and far-field coupling, but we have verified by RCWA that the coupling is real with good approximation in the next section. Here we assume the representation with near-field coupling κ12. Considering the general dynamical equations with both modes having the same losses included all in γa = 1/τa, it is possible to write, \(\forall {\bf{k}}:{\bf{k}}\simeq {{\bf{k}}}_{{\rm{BIC}}}\) that

    $$\frac{{\rm{d}}{A}_{-}}{{\rm{d}}t}=j{\omega }_{-}\,{A}_{-}-\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}1}}\right){A}_{-}+j{\kappa }_{12}{A}_{+}+\sqrt{\frac{2}{{\tau }_{{\rm{R}}1}}}{s}_{+},$$

    (34)

    $$\frac{{\rm{d}}{A}_{+}}{{\rm{d}}t}=j{\omega }_{+}\,{A}_{+}-\left(\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}2}}\right){A}_{+}+j{\kappa }_{12}A\_+\sqrt{\frac{2}{{\tau }_{{\rm{R}}2}}}{s}_{+}.$$

    (35)

    This set of equations is valid for any system (for example, plasmonic modes, whispering-gallery modes, guided modes, defect modes). Considering \(\frac{{\rm{d}}}{{\rm{d}}t}\to j{\omega }_{{\rm{in}}}\) and solving for A in equation (34), substituting it in equation (35) and then substituting the resulting A+ again in equation (34), we find, at the steady state, that

    $$\begin{array}{l}\frac{{A}_{-}({\omega }_{{\rm{in}}})}{{s}_{+}}=\frac{\sqrt{\frac{2}{{\tau }_{{\rm{R}}1}}}}{j({\omega }_{{\rm{in}}}-{\omega }_{-})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}1}}}+\\ +\frac{j/{\tau }_{\kappa }\sqrt{\frac{2}{{\tau }_{{\rm{R}}2}}}}{\left[j({\omega }_{{\rm{in}}}-{\omega }_{-})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}1}}\right]\left[j({\omega }_{{\rm{in}}}-{\omega }_{+})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}2}}+\frac{1/{\tau }_{\kappa }^{2}}{j({\omega }_{{\rm{in}}}-{\omega }_{-})+1/{{\rm{\tau }}}_{a}+1/{{\rm{\tau }}}_{R1}}\right]}+\\ -\frac{1/{{\rm{\tau }}}_{{\rm{\kappa }}}^{2}\sqrt{\frac{2}{{{\rm{\tau }}}_{R1}}}}{{\left[j({\omega }_{{\rm{in}}}-{\omega }_{-})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}1}}\right]}^{2}\left[j({\omega }_{{\rm{in}}}-{\omega }_{+})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}2}}+\frac{1/{\tau }_{\kappa }^{2}}{j({\omega }_{{\rm{in}}}-{\omega }_{-})+1/{\tau }_{{\rm{a}}}+1/{\tau }_{{\rm{R}}1}}\right]},\end{array}$$

    (36)

    $$\begin{array}{l}\frac{{A}_{+}({\omega }_{{\rm{in}}})}{{s}_{+}}=\frac{\sqrt{\frac{2}{{\tau }_{{\rm{R}}2}}}}{j({\omega }_{{\rm{in}}}-{\omega }_{+})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}2}}+\frac{1/{\tau }_{\kappa }^{2}}{j({\omega }_{{\rm{in}}}-{\omega }_{-})+1/{\tau }_{{\rm{a}}}+1/{\tau }_{{\rm{R}}1}}}+\\ +\frac{j/{\tau }_{\kappa }\sqrt{\frac{2}{{\tau }_{{\rm{R}}1}}}}{\left[j({\omega }_{{\rm{in}}}-{\omega }_{-})+\frac{1}{{\tau }_{a}}+\frac{1}{{\tau }_{{\rm{R}}1}}\right]\left[j({\omega }_{{\rm{in}}}-{\omega }_{+})+\frac{1}{{\tau }_{{\rm{a}}}}+\frac{1}{{\tau }_{{\rm{R}}2}}+\frac{1/{\tau }_{\kappa }^{2}}{j({\omega }_{{\rm{in}}}-{\omega }_{-})+1/{\tau }_{{\rm{a}}}+1/{\tau }_{{\rm{R}}1}}\right]}.\end{array}$$

    (37)

    Above, we have explicitly defined the near-field coupling lifetime \({{\rm{\tau }}}_{{\rm{\kappa }}}=\frac{1}{{{\rm{\kappa }}}_{12}}\) and the associated quality factor τκ = 2Qκ/ω. We can see that the quasi-dark mode A can be excited by means of internal coupling κ12 more than what is expected from the isolated resonance response of the dark mode, represented by the first term in equation (36) (in Supplementary Information section 1.2 and Supplementary Fig. 4, the mediated drive term is also made explicit in the original quantum model)2. In Extended Data Fig. 1b–d, the behaviour for both mode intensities for a specific set of informative values, QR1 = 5 × 109, QR2 = 200, Qa = 5,000 is plotted to capture the main insight. In Extended Data Fig. 1b, the intensity field enhancement

    $$G=\frac{{\left|{A}_{\pm }\right|}^{2}}{{\left|{s}_{+}/\sqrt{{\omega }_{{\rm{in}}}}\right|}^{2}{V}_{{\rm{eff}}}}$$

    (38)

    is plotted for both modes (solid red line for the dark A and blue line for the bright A+), showing that the dark mode on resonance (ωin = ω) reaches the maximum limit of field enhancement possible in a real-world resonator with non-radiative loss, Gmax = Qa/Veff, even if

    $${Q}_{{\rm{R}}1}\gg {Q}_{{\rm{a}}},$$

    (39)

    which would be impossible in case of a single dark resonance, that is, not coupled to another wave (dashed red line). This condition occurs at the supercritical coupling point defined by

    $${\bar{\tau }}_{\kappa }=\sqrt{{\tau }_{{\rm{R}}2}{\tau }_{{\rm{a}}}},$$

    (40)

    or

    $${\bar{Q}}_{\kappa }=\sqrt{{{Q}_{{\rm{R}}2}Q}_{{\rm{a}}}}.$$

    (41)

    Indeed, assuming τR1τa, τR2, τκ and τR2 < τa in equation (36) and considering ωin = ω (on resonance with the dark mode) and |ωin − ω+|  2κ12 = 2/τκ (the coupling affects the split in frequencies, thus the pump is shifted from the bright mode when on resonance with the dark one), the relation simplifies as

    $$\frac{{A}_{-}\left({\omega }_{{\rm{in}}}={\omega }_{-}\right)}{{s}_{+}}\to {\left[\frac{j/{\tau }_{\kappa }\sqrt{\frac{2}{{\tau }_{{\rm{R}}2}}}}{j/\left({\tau }_{\kappa }{\tau }_{{\rm{a}}}\right)+1/{\tau }_{{\rm{a}}}^{2}+1/\left({\tau }_{{\rm{R}}2}{\tau }_{{\rm{a}}}\right)+1/{\tau }_{\kappa }^{2}}\right]}_{{\bar{{\rm{\tau }}}}_{\kappa }=\sqrt{{\tau }_{{\rm{R}}2}{\tau }_{{\rm{a}}}}}\to j\sqrt{{\tau }_{{\rm{a}}}/2},$$

    (42)

    in which the first two terms in the denominator were neglected, as they are smaller when τR2 < τa. The above relation proves that the dark-mode intensity enhancement \(G={| \frac{{A}_{-}\left({\omega }_{{\rm{in}}}={\omega }_{-}\right)}{{s}_{+}/\sqrt{{\omega }_{{\rm{in}}}}}| }^{2}\frac{1}{{V}_{{\rm{eff}}}}={Q}_{{\rm{a}}}/{V}_{{\rm{eff}}}={G}_{\max }\), that is, it can reach the maximum imposed by non-radiative losses even in extreme situations with mismatched quality factors. It is worth mentioning that, when Qκ → ∞ (κ12 → 0), we again obtain the correct case of uncoupled resonances and the dark-mode field goes to the level it could gain if it were isolated (dashed red line). Indeed, in the plot, we have specified that the near-field coupling rate affects the spectral separation among resonances, as it is proportional to their distance: ω± = ωo ± κ12 = ωo[1 ± 1/(2Qκ)] Thus, for Qκ → ∞, the resonant frequencies coincide and cross. Even when out of perfect spectral tuning, the maximum gain achieved by the quasi-dark mode A is orders of magnitudes larger than what possible in a single dark mode, as shown in Extended Data Fig. 1c,d. In case ωin = ωo = 1/2(ω+ + ω), the optimum shifts to larger Q*κQa. When QR2 → Qa and ωin = ω, the bright mode is critically coupled with the pump, but there is still energy going into the dark mode up to 0.3Gmax at a certain \({{Q}^{* }}_{\kappa }\lesssim {\bar{Q}}_{\kappa }={Q}_{{\rm{a}}}\). Furthermore, by inspecting the ratio between the solid red line and the dashed red line, it is possible to appreciate how, even if Qκ does not reach the optimum, the intensity of the coupled dark resonance is orders of magnitude larger than that of the single resonance.

    Further discussion

    The supercritical coupling mechanism guarantees the possibility of achieving the maximum level of local field enhancement when the coupling (Qκ) is optimally tuned, and always in the highest Q-factor mode, even under the conditions of coupling, for both bright and dark modes, which would be unfavourable in the case of single isolated modes. To give an example, let QR2 = 103Qa = 106 QR1 = 1010, thus none of the modes matches Qa; by contrast, they have completely unmatched quality factors. If \({Q}_{\kappa }=\sqrt{{10}^{3}\times {10}^{6}}\simeq 3\times {10}^{4}\) (say, Veff = 1 for brevity), the dark mode reaches the maximum intensity enhancement Gmax = 106, although the intensity enhancement of the single dark resonance would be only 102, that is, four orders of magnitude less, as shown in Fig. 1e. Also, the supercritical coupling condition is independent of the highest Q-factor resonance, unlike the critical coupling condition (QR1 = Qa); the model converges to the critical-coupling result if QR1 → Qa and can ensure a higher level of enhancement in the dark mode, with a considerable advantage over the single-dark-resonance case, even when QR2 and Qκ vary over a considerably large range of values. This is shown for fixed \({\bar{Q}}_{\kappa }=\sqrt{{{Q}_{{\rm{R2}}}Q}_{{\rm{a}}}}\) in Extended Data Fig. 1e.

    This mechanism holds true for all wavevectors that span the range from an FW quasi-BIC to the EIT point (if this is also present in the system), with correspondingly varied values of the parameters involved (coupled mode frequencies, decay rates and near-field coupling). Far from this momentum region, the mode coupling becomes progressively negligible (as it can be easily calculated numerically) and the isolated single mode response is restored.

    Turning to the parallel with coupled-resonance-induced transparency, we understand that, at the dark mode frequency ωt = ω′ (equations (25) and (29)), in which the transparency window occurs, the fast dispersion leads to slow light and an enhanced field that, with suitable coupling between modes, could reach the maximum field enhancement of the system, as indicated by supercritical coupling. We recall that EIT is not a necessary condition for the FW mechanism, although it may widen, if present, the wavevector span of an enhanced field.

    RCWA validation

    The validity of TCMT is confirmed through numerical simulations using full 3D RCWA. RCWA simulations are performed using the Fourier modal expansion method (Ansys Lumerical, RCWA module). Validation is performed by evaluating the exact transmittance spectra, the 3D-vector-field distribution of the interfering modes, their complex coupling constant, their evolution with momentum, the near-field coupling at EIT, FW quasi-BIC and FW-BIC points in momentum space. The modes belonging to the dispersion curves are a linear combination of tens to hundreds of Fourier plane waves in each xy-periodic, z-homogeneous layer satisfying the continuity boundary conditions in each z layer of the structure (with forward and backward propagating factors along the z axis), providing the exact solution of the problem, including material dispersion, matching the experimental transmittance spectrum measured to reconstruct the energy–momentum band diagrams for both s-polarized (vector TE-like character) and p-polarized (vector TM-like character) excitation. RCWA is indeed used as a benchmark for validating other numerical techniques such as resonant-state expansion, quasi-normal modes and other methods. It provides the 3D vector fields and the exact solution, which can be analytically approximated by the leaky TE-like and TM-like modes of the effective waveguide, or TCMT. Further details are in Supplementary Information with measured refractive index dispersion (Supplementary Fig. 1) and details on fitting, giving imaginary refractive index used for simulations nI = 10−4 over the spectral range 700–1,200 nm.

    Extended Data Fig. 2a shows the theoretical TE bands expected for a uniform film of upconversion nanoparticles (UCNPs) with a refractive index of 1.45, matching the experimental absorption band of UCNPs in Extended Data Fig. 2b. Extended Data Fig. 2c shows the mode distribution, whereas Extended Data Fig. 2d evaluates the mode energy fraction superimposed on the nonlinear material as a function of refractive index, for one layer (1L), two layers (2L) and with a cladding of air or silicone oil. The silicone oil promotes vertical symmetry, which means that it increases the field overlap with the UCNPs and helps minimize scattering losses, but it cannot affect the vertical symmetry of the TE-like and TM-like modes, which is determined mainly by the different refractive index of the glass substrate, silicon nitride and UCNPs index. Indeed, the energy fraction with silicone oil only changes from 8% to 9% (Extended Data Fig. 2d). Nonetheless, silicone oil was often useful to better observe the side emission, as the silicone layer acted as a partially opaque screen crossing the outcoupled light (as shown in Fig. 3b). Note that the silicone oil layer was not used in Fig. 4b.

    Extended Data Fig. 3 shows the evolution of the transmittance spectra by changing the azimuthal angle of incidence ϕ. The avoided crossing stops only when the two modes no longer intersect, as shown clearly in Extended Data Fig. 3b at ϕ = 45°, at which it is also possible to observe that the uncoupled mode 1 has linewidth larger than mode 2, that is, γr1γr2. Extended Data Fig. 3c,d shows the details of FW quasi-BIC and avoided crossing.

    Extended Data Fig. 4 shows that vector TE-like and TM-like modes evolve and change symmetry along the momentum; they are, in general, non-orthogonal and nearly coincident at the avoided crossing (and approximately even with respect to the z-mirror symmetry). Because the modes are nearly coincident, the approximation γa = 1/τa in the above model, that is, the same for both modes, is correct. Also, because the input intensity is Iinput = 1, the resonance field intensity is much larger than what would be expected on the basis of critical coupling (material absorption loss, nI = 10−4 is included in the simulation), providing an estimate of the field enhancement (I1 > 3 × 104Iinput).

    Extended Data Fig. 5a shows the spectral coincidence of the coupled-resonance-induced transparency (EIT) frequency (for θ = 2.7° at the avoided crossing) with the FW quasi-BIC frequency at θ = 3.15° for the angle mismatch <0.5° (mismatched momentum kEIT = kBIC + δk). The existence of coupled-resonance-induced transparency can only occur for non-orthogonal modes25, and the proximity in momentum space to the BIC point proves that FW-BIC is an ideal condition originating from the evolution of non-orthogonal modes. Extended Data Fig. 5b shows the near-field coupling constant normalized to ω = 2πc/λmodel calculated using the formula in ref. 54 (equation (4.13), page 162, including material distribution), for θ from 2.7° (EIT) to 3.24° (nearly ideal FW-BIC). The phase mismatch is minimal, thus the two modes also exchange energy along the propagation (Pendellösung effect), as it commonly occurs between two modes of the same waveguide coupled by a periodic modulation15,54. The near-field coupling was calculated as

    $${\kappa }_{12}=\frac{1}{4}\sqrt{\frac{{\varepsilon }_{{\rm{o}}}}{{\mu }_{{\rm{o}}}}}\frac{{k}_{{\rm{o}}}}{\sqrt{{N}_{1}{N}_{2}}}\int \left(\varepsilon -{\varepsilon }_{{\rm{o}}}\right){{{\bf{E}}}_{1}}^{\star }\cdot {{\bf{E}}}_{2}{\rm{d}}A,$$

    in which \({N}_{{\rm{1,2}}}=\frac{1}{2}| \int ({{{\bf{E}}}^{* }}_{1,2}\times {{\bf{H}}}_{1,2}+{\bf{c}}.{\bf{c}}.)\cdot \widehat{z}{\rm{d}}A| \) are optical power normalizations. The integral is over the unitary cell area A. Note that the calculation provides the complex κ12, in which the imaginary part of κ12 is to be understood as a representation of ζ12 in equation (26) above. We estimated that ζ12 < 10−4κ12 for all modes in the range θ (0°, 5°), thus ζ12 0. Also, we found that κ12κ21, as expected. The near-field coupling is stronger at the EIT point, whereas it decreases at the ideal FW-BIC, in agreement with the behaviour expected from the temporally coupled mode theory. As the incidence angle varies from the EIT point (2.7°) to the ideal position of the BIC (3.24°), Qκ = τκ ω/2 varies accordingly and is characterized by a \({Q}_{\kappa }\approx ({10}^{3},{10}^{4})\approx \sqrt{{Q}_{{\rm{R2}}}{Q}_{{\rm{a}}}}\) at the FW quasi-BIC mode (dashed black line, 3.15°). As the near-field coupling is modulated, the fulfilment of the supercritical coupling condition can be tuned.

    Supplementary Fig. 2 shows the evolution of the interference process as a function of κ12 and describes how the coupling changes at the edge. The effect of the finite boundary on resonance was investigated using near-field scanning optical microscopy (Witec Alpha RAS 300) and shown in Supplementary Fig. 3.

    Supplementary Fig. 4 shows theoretical linewidths calculated with the original FW quantum model2, revealing that the open-channel wave acts as a drive field in the coupled BIC equation, for representative near-field coupling values.

    Fabrication

    Extended Data Fig. 6 shows the energy-level scheme of the produced UCNPs. All materials and synthesis details of NPs, NP characterization, PCNS fabrication and characterization are in Supplementary Information sections 2–4 and Supplementary Figs. 5 and 6.

    Optical characterization

    Dispersion-band-diagram measurements, experimental interrogation and detection scheme of upconversion are provided, respectively, in Supplementary Information sections 5 and 6 and Supplementary Figs. 7–10. For upconversion, the pulsed (150-fs) Ti:Sa oscillator, with central wavelength λin = 810 nm and full-width at half-maximum of 6 nm, is tuned to the FW quasi-BIC and focused to a 6-µm spot on the PCNS. The power coupled with NPs was 5%, corresponding to 48 kW cm−2 at a pulse energy of 6.25 nJ (103 kW cm−2).

    Photoluminescence, enhancement-factor and radiance-enhancement estimation

    Enhancement-factor estimation, spectral emission datasets from samples and radiance-enhancement-factor estimation are provided, respectively, in Supplementary Information section 7 and Supplementary Figs. 11 and 12.

    FDTD simulations

    The radiation properties of the PCNS were evaluated using the FDTD method in Ansys Lumerical. A single dipole source was used to compute the isofrequency map using the Z-transform of the local optical field retrieved within the finite-structure domain with the 3D full-field monitor. The intensity of the Z-transform determines the strength of radiation in the momentum space and better represents the radiation properties associated with the PCNS. To validate the results found with this approach, we first simulated a literature case discussed in ref. 44, that is, supercollimation resulting from flat-band dispersion in the momentum space, which is shown in Supplementary Fig. 13. The isofrequency far-field intensity map in momentum space showed, in our case, non-trivial vanishing strips along orthogonal arms (cross of zeros; Fig. 3 and Extended Data Fig. 7). The near-field intensity map showed self-collimation as occurring when flat dispersion is involved. In Extended Data Fig. 7e, the experimental proof is reported using a rescaled geometry of the PCNS (using the fit in Extended Data Fig. 2e) to move the FW-BIC at 532 nm and make the beam easily visible. At this stage, the radiation properties were examined by placing an array of dipole sources (18 × 18) at the boundary of the finite PCNS with a uniform slab covering an area of several microns squared. The results are shown in Fig. 3c and Extended Data Fig. 8. The sources collectively add up their field and coherently emit radiation in the plane of the slab, as shown in Extended Data Fig. 8a, in which the field propagates along the direction (+1, 0) with intensity enhancement as large as 1.5 × 104 (normalized to the number of emitters). The emission was always pointing towards the non-textured slab, thus—on the opposite edge—the propagation was along the direction (−1, 0). It was found that, at shorter wavelengths, other preferential directions of propagation were also possible, such as (1, ±1). The divergence was evaluated along 1 mm of propagation from the edge, as shown in Extended Data Fig. 8b, which showed a divergence of 0.02° (Extended Data Fig. 8c), which is even lower than the experimental values. Analysis of the whole visible and near-infrared spectrum revealed that the typical value of the divergence is less than 0.5° (Extended Data Fig. 8d), demonstrating that this regime of narrow radiation is expected to be common in this type of photonic structure. Indeed, as shown in Extended Data Fig. 8e, the full width at half maximum of the beam periodically contracts and expands  along the propagation, which is because of a mechanism of self-healing that compensates for diffraction.

    Directivity measurements

    Extended Data Fig. 9a shows the microscopy inspection of light propagation near the edge. Extended Data Fig. 9b shows the experimental results on the divergence of the side beam (directed along the outer edge versor), with a polar plot of the edge emission in Extended Data Fig. 9c, in agreement with simulation in Extended Data Fig. 8 in the upconverted emission.

    [ad_2]

    Source link

  • Room temperature operation of germanium–silicon single-photon avalanche diode

    [ad_1]

  • Politi, A., Matthews, J. C. F. & O’Brien, J. L. Shor’s quantum factoring algorithm on a photonic chip. Science 325, 1221 (2009).

    Article 
    ADS 
    MathSciNet 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhong, H.-S. et al. Quantum computational advantage using photons. Science 370, 1460–1463 (2020).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Waks, E. et al. Quantum cryptography with a photon turnstile. Nature 420, 762 (2002).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Lai, S.-K. et al. Satellite-relayed intercontinental quantum network. Phys. Rev. Lett. 120, 030501 (2018).

    Article 
    ADS 

    Google Scholar
     

  • Brida, G., Genovese, M. & Ruo Berchera, I. Experimental realization of sub-shot-noise quantum imaging. Nat. Photon. 4, 227–230 (2010).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Zarghami, M. et al. A 32 × 32-pixel CMOS imager for quantum optics with per-SPAD TDC, 19.48% fill-factor in a 44.64-μm pitch reaching 1-MHz observation rate. IEEE J. Solid-State Circuits 55, 2819–2830 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Bruschini, C., Homulle, H., Antolovic, I. M., Burri, S. & Charbon, E. Single-photon avalanche diode imagers in biophotonics: review and outlook. Light Sci. Appl. 8, 87 (2019).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pawlikowska, A. M., Halimi, A., Lamb, R. A. & Buller, G. S. Single-photon three-dimensional imaging at up to 10 kilometers range. Opt. Express 25, 11919–11931 (2017).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Kuzmenko, K. et al. 3D LIDAR imaging using Ge-on-Si single-photon avalanche diode detectors. Opt. Express 28, 1330–1344 (2020).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Entwistle, M. et al. Geiger-mode APD camera system for single-photon 3D LADAR imaging. In Proc. SPIE Vol. 8375, Advanced Photon Counting Techniques VI, 83750D (SPIE, 2012).

  • Morimoto, K. et al. Megapixel time-gated SPAD image sensor for 2D and 3D imaging applications. Optica 7, 346–354 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Hadfield, R. H. Single-photon detectors for optical quantum information applications. Nat. Photon. 3, 696–705 (2009).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Marsili, F. et al. Detecting single infrared photons with 93% system efficiency. Nat. Photon. 7, 210–214 (2013).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Najafi, F. et al. On-chip detection of non-classical light by scalable integration of single-photon detectors. Nat. Commun. 6, 5873 (2015).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Campbell, J. C., Sun, W., Lu, Z., Itzler, M. A. & Jiang, X. Common-mode cancellation in sinusoidal gating with balanced InGaAs/InP single photon avalanche diodes. IEEE J. Quantum Electron. 47, 1505–1511 (2012).

    Article 
    ADS 

    Google Scholar
     

  • Signorelli, F. et al. Low-noise InGaAs/InP single-photon avalanche diodes for fiber-based and free-space applications. IEEE J. Sel. Top. Quantum Electron. 28, 3801310 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Xu, H., Pancheri, L., Dalla Betta, G.-F. & Stoppa, D. Design and characterization of a p+/n-well SPAD array in 150nm CMOS process. Opt. Express 25, 12765–12778 (2017).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Lee, M.-J. et al. High-performance back-illuminated three-dimensional stacked single-photon avalanche diode implemented in 45-nm CMOS technology. IEEE J. Sel. Top. Quant. Electron. 24, 3801809 (2018).

    Article 

    Google Scholar
     

  • Sliney, D. H. & Freasier, B. C. Evaluation of optical radiation hazards. Appl. Opt. 12, 1–24 (1973).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Bird, R. E., Hulstrom, R. L. & Lewis, L. J. Terrestrial solar spectral data sets. Sol. Energy 30, 563–574 (1983).

    Article 
    ADS 

    Google Scholar
     

  • Arnulf, A., Bricardi, J., Cura, E. & Varet, C. Transmission by haze and fog in the spectral region 0.35 to 10 microns. J. Opt. Soc. Am. 47, 491–498 (1957).

    Article 
    ADS 

    Google Scholar
     

  • Loudon, A. Y. et al. Enhancement of the infrared detection efficiency of silicon photon-counting avalanche photodiodes by use of silicon germanium absorbing layers. Opt. Lett. 27, 219–221 (2002).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Tosi, A., Dalla Mora, A., Zappa, F. & Cova, S. Germanium and InGaAs/InP SPADs for single-Photon detection in the near-infrared. In Proc. SPIE Vol. 6771, Advanced Photon Counting Techniques II, 67710P (SPIE, 2007).

  • Lu, Z. et al. Geiger-mode operation of Ge-on-Si avalanche photodiodes. IEEE J. Quantum Electron. 47, 731–735 (2011).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Warburton, R. E. et al. Ge-on-Si single-photon avalanche diode detectors: design, modeling, fabrication, and characterization at wavelengths 1310 and 1550 nm. IEEE Trans. Electron Devices 60, 3807–3813 (2013).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Martinez, N. J. D. et al. Single photon detection in a waveguide-coupled Ge-on-Si lateral avalanche photodiode. Opt. Express 25, 161310–16139 (2017).

    Article 

    Google Scholar
     

  • Vines, P. et al. High performance planar germanium-on-silicon single-photon avalanche diode detectors. Nat. Commun. 10, 1086 (2019).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ferre Llin, L. et al. High sensitivity Ge-on-Si single-photon avalanche diode detectors. Opt. Lett. 45, 6406–6409 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Ke, S. et al. Design of wafer-bonded structures for near room temperature Geiger-mode operation of germanium on silicon single-photon avalanche photodiode. Appl. Opt. 56, 4646–4653 (2017).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Soref, R. A., De Leonardis, F. & Passaro, V. M. N. Simulations of nanoscale room temperature waveguide-coupled single-photon avalanche detectors for silicon photonic sensing and quantum applications. ACS Appl. Nano Mater. 2, 7503–7512 (2019).

    Article 
    CAS 

    Google Scholar
     

  • Thorburn, F. et al. Ge-on-Si single-photon avalanche diode detectors for short-wave infrared wavelengths. J. Phys. Photonics 4, 012001 (2022).

    Article 
    ADS 

    Google Scholar
     

  • Samavedam, S. B., Currie, M. T., Langdo, T. A. & Fitzgerald, E. A. High-quality germanium photodiodes integrated on silicon substrates using optimized relaxed graded buffers. Appl. Phys. Lett. 73, 2125–2127 (1998).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Luan, H.-C. et al. High-quality Ge epilayers on Si with low threading-dislocation densities. Appl. Phys. Lett. 75, 2909–2911 (1999).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Osmond, J. et al. Ultralow dark current Ge/Si(100) photodiodes with low thermal budget. Appl. Phys. Lett. 94, 201106 (2009).

    Article 
    ADS 

    Google Scholar
     

  • Åberg, I. et al. A low dark current and high quantum efficiency monolithic germanium-on-silicon CMOS imager technology for day and night imaging applications. In Proc. 2010 International Electron Devices Meeting (IEDM) 14.4.1–14.4.4 (IEEE, 2010).

  • Lee, K.-H. et al. Defects reduction of Ge epitaxial film in a germanium-on-insulator wafer by annealing in oxygen ambient. APL Mater. 3, 016102 (2015).

    Article 
    ADS 

    Google Scholar
     

  • Morse, M., Dosunmu, O., Sarid, G. & Chetrit, Y. Performance of Ge-on-Si p-i-n photodetectors for standard receiver modules. IEEE Photon. Technol. Lett. 18, 2442–2444 (2006).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Takenaka, M., Morii, K., Sugiyama, M., Nakano, Y. & Takagi, S. Dark current reduction of Ge photodetector by GeO2 surface passivation and gas-phase doping. Opt. Express 20, 8718–8725 (2012).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Sammak, A., Aminian, M., Nanver, L. K. & Charbon, E. CMOS-compatible PureGaB Ge-on-Si APD pixel arrays. IEEE Trans. Electron Devices 63, 92–99 (2016).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Kang, Y. et al. Monolithic germanium/silicon avalanche photodiodes with 340 GHz gain–bandwidth product. Nat. Photon. 3, 59–63 (2008).

    Article 
    ADS 

    Google Scholar
     

  • Duan, N., Liow, T.-Y., Lim, A. E.-J., Ding, L. & Lo, G. Q. 310 GHz gain-bandwidth product Ge/Si avalanche photodetector for 1550 nm light detection. Opt. Express 20, 11031–11036 (2012).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Huang, M. et al. Germanium on silicon avalanche photodiode. IEEE J. Sel. Top. Quantum Electron. 24, 3800911 (2018).

    Article 

    Google Scholar
     

  • Assefa, S., Xia, F. & Vlasov, Y. A. Reinventing germanium avalanche photodetector for nanophotonic on-chip optical interconnects. Nature 464, 80–84 (2010).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Virot, L. et al. Germanium avalanche receiver for low power interconnects. Nat. Commun. 5, 4957 (2014).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen, H. T. et al. High sensitivity 10Gb/s Si photonic receiver based on a low-voltage waveguide-coupled Ge avalanche photodetector. Opt. Express 23, 815–822 (2015).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Su, Y. K., Chang, C. Y. & Wu, T. S. Temperature dependent characteristics of a PIN avalanche photodiode (APD) in Ge, Si and GaAs. Opt. Quantum Electron. 11, 109–117 (1979).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Hofbauer, M., Steind, B. & Zimmermann, H. Temperature dependence of dark count rate and after pulsing of a single-photon avalanche diode with an integrated active quenching circuit in 0.35 μm CMOS. J. Sens. 2018, 9585931 (2018).

    Article 

    Google Scholar
     

  • Mahmoudi, H., Hofbauer, M., Goll, B. & Zimmermann, H. Noise and breakdown characterization of SPAD detectors with time-gated photon-counting operation. Sensors 21, 5287 (2021).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ziarkash, A. W., Joshi, S. K., Stipčević, M. & Ursin, R. Comparative study of afterpulsing behavior and models in single photon counting avalanche photo diode detectors. Sci. Rep. 8, 5076 (2018).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Na, N. et al. High-performance germanium-on-silicon lock-in pixels for indirect time-of-flight applications. In Proc. 2018 International Electron Devices Meeting (IEDM) 32.4.1–32.4.4 (2018).

  • [ad_2]

    Source link

  • A lanthanide-rich kilonova in the aftermath of a long gamma-ray burst

    [ad_1]

  • Eichler, D., Livio, M., Piran, T. & Schramm, D. N. Nucleosynthesis, neutrino bursts and γ-rays from coalescing neutron stars. Nature 340, 126–128 (1989).

    Article 
    ADS 

    Google Scholar
     

  • Li, L.-X. & Paczyński, B. Transient events from neutron star mergers. Astrophys. J. 507, L59–L62 (1998).

    Article 
    ADS 

    Google Scholar
     

  • Freiburghaus, C., Rosswog, S. & Thielemann, F. K. R-process in neutron star mergers. Astrophys. J. 525, L121–L124 (1999).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Korobkin, O., Rosswog, S., Arcones, A. & Winteler, C. On the astrophysical robustness of the neutron star merger r-process. Mon. Not. R. Astron. Soc. 426, 1940–1949 (2012).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Barnes, J., Kasen, D., Wu, M.-R. & Martínez-Pinedo, G. Radioactivity and thermalization in the ejecta of compact object mergers and their impact on kilonova light curves. Astrophys. J. 829, 110 (2016).

    Article 
    ADS 

    Google Scholar
     

  • Hotokezaka, K. & Nakar, E. Radioactive heating rate of r-process elements and macronova light curve. Astrophys. J. 891, 152 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Zhu, J.-P. et al. Long-duration gamma-ray burst and associated kilonova emission from fast-spinning black hole–neutron star mergers. Astrophys. J. 936, L10 (2022).

    Article 
    ADS 

    Google Scholar
     

  • Wollaeger, R. T. et al. Impact of pulsar and fallback sources on multifrequency kilonova models. Astrophys. J. 880, 22 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Levan, A. et al. Heavy element production in a compact object merger observed by JWST. Nature https://doi.org/10.1038/s41586-023-06759-1 (2023).

  • Sun, H. et al. Magnetar emergence in a peculiar gamma-ray burst from a compact star merger. Preprint at https://arxiv.org/abs/2307.05689 (2023).

  • Bloom, J. S., Kulkarni, S. R. & Djorgovski, S. G. The observed offset distribution of gamma-ray bursts from their host galaxies: a robust clue to the nature of the progenitors. Astron. J. 123, 1111–1148 (2002).

    Article 
    ADS 

    Google Scholar
     

  • Freedman, W. L. et al. The Carnegie-Chicago Hubble Program. VIII. An independent determination of the Hubble constant based on the tip of the red giant branch. Astrophys. J. 882, 34 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Waxman, E., Ofek, E. O. & Kushnir, D. Late-time kilonova light curves and implications to GW170817. Astrophys. J. 878, 93 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Kasliwal, M. M. et al. Spitzer mid-infrared detections of neutron star merger GW170817 suggests synthesis of the heaviest elements. Mon. Not. R. Astron. Soc. 510, L7–L12 (2022).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Troja, E. et al. A nearby long gamma-ray burst from a merger of compact objects. Nature 612, 228–231 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gehrels, N. et al. A new γ-ray burst classification scheme from GRB060614. Nature 444, 1044–1046 (2006).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Yang, B. et al. A possible macronova in the late afterglow of the long-short burst GRB 060614. Nat. Commun. 6, 7323 (2015).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Jin, Z.-P. et al. The light curve of the macronova associated with the long-short burst GRB 060614. Astrophys. J. 811, L22 (2015).

    Article 
    ADS 

    Google Scholar
     

  • Rastinejad, J. C. et al. A kilonova following a long-duration gamma-ray burst at 350 Mpc. Nature 612, 223–227 (2022).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Yang, J. et al. A long-duration gamma-ray burst with a peculiar origin. Nature 612, 232–235 (2022).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Ryan, G., van Eerten, H., Piro, L. & Troja, E. Gamma-ray burst afterglows in the multimessenger era: numerical models and closure relations. Astrophys. J. 896, 166 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Valenti, S. et al. The diversity of type II supernova versus the similarity in their progenitors. Mon. Not. R. Astron. Soc. 459, 3939–3962 (2016).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Barnes, J. et al. Kilonovae across the nuclear physics landscape: the impact of nuclear physics uncertainties on r-process-powered emission. Astrophys. J. 918, 44 (2021).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Frey, L. H. et al. The Los Alamos Supernova Light-curve Project: computational methods. Astrophys. J. 204, 16 (2013).

    Article 

    Google Scholar
     

  • Fontes, C. J., Fryer, C. L., Hungerford, A. L., Wollaeger, R. T. & Korobkin, O. A line-binned treatment of opacities for the spectra and light curves from neutron star mergers. Mon. Not. R. Astron. Soc. 493, 4143–4171 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Fontes, C. J., Fryer, C. L., Wollaeger, R. T., Mumpower, M. R. & Sprouse, T. M. Actinide opacities for modelling the spectra and light curves of kilonovae. Mon. Not. R. Astron. Soc. 519, 2862–2878 (2023).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Zhu, Y. et al. Californium-254 and kilonova light curves. Astrophys. J. 863, L23 (2018).

    Article 
    ADS 

    Google Scholar
     

  • Holmbeck, E. M. et al. Superheavy elements in kilonovae. Astrophys. J. 951, L13 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Waxman, E., Ofek, E. O., Kushnir, D. & Gal-Yam, A. Constraints on the ejecta of the GW170817 neutron star merger from its electromagnetic emission. Mon. Not. R. Astron. Soc. 481, 3423–3441 (2018).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Arnaud, K. A. XSPEC: the first ten years. In Astronomical Data Analysis Software and Systems V, Conference Series Vol. 101 (eds Jacoby, G. H. & Barnes, J.) 17–20 (Astronomical Society of the Pacific, 1996).

  • Willingale, R., Starling, R. L. C., Beardmore, A. P., Tanvir, N. R. & O’Brien, P. T. Calibration of X-ray absorption in our Galaxy. Mon. Not. R. Astron. Soc. 431, 394–404 (2013).

    Article 
    ADS 

    Google Scholar
     

  • Schlafly, E. F. & Finkbeiner, D. P. Measuring reddening with Sloan Digital Sky Survey stellar spectra and recalibrating SFD. Astrophys. J. 737, 103 (2011).

    Article 
    ADS 

    Google Scholar
     

  • Waxman, E., Ofek, E. O. & Kushnir, D. Strong NIR emission following the long duration GRB 211211A: dust heating as an alternative to a kilonova. Preprint at https://arxiv.org/abs/2206.10710 (2022).

  • Krühler, T. et al. The SEDs and host galaxies of the dustiest GRB afterglows. Astron. Astrophys. 534, A108 (2011).

    Article 

    Google Scholar
     

  • Sneppen, A. et al. Spherical symmetry in the kilonova AT2017gfo/GW170817. Nature 614, 436–439 (2023).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Levan, A. J. et al. GRB 230307A: JWST NIRSpec observations, possible higher redshift. GRB Coord. Netw. Circ. No. 33580 (2023).

  • Windhorst, R. A. et al. JWST PEARLS. Prime Extragalactic Areas for Reionization and Lensing Science: project overview and first results. Astron. J. 165, 13 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Chang, H.-Y. & Kim, H.-I. On spatial distribution of short gamma-ray bursts from extragalactic magnetar flares. J. Astron. Space Sci. 19, 1–6 (2002).

    Article 
    ADS 

    Google Scholar
     

  • Dichiara, S. et al. A luminous precursor in the extremely bright GRB 230307A. Astrophys. J. 954, L29 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Yang, J. et al. GRB 200415A: a short gamma-ray burst from a magnetar giant flare? Astrophys. J. 899, 106 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Wang, Y., Xia, Z.-Q., Zheng, T.-C., Ren, J. & Fan, Y.-Z. A broken “α–intensity” relation caused by the evolving photosphere emission and the nature of the extraordinarily bright GRB 230307A. Astrophys. J. 953, L8 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Planck Collaboration et al. Planck 2018 results. VI. Cosmological parameters. Astron. Astrophys. 641, A6 (2020).

    Article 

    Google Scholar
     

  • O’Connor, B. et al. A deep survey of short GRB host galaxies over z ~ 0–2: implications for offsets, redshifts, and environments. Mon. Not. R. Astron. Soc. 515, 4890–4928 (2022).

    Article 
    ADS 

    Google Scholar
     

  • Jin, Z.-P. et al. A kilonova associated with GRB 070809. Nat. Astron. 4, 77–82 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • O’Connor, B., Beniamini, P. & Kouveliotou, C. Constraints on the circumburst environments of short gamma-ray bursts. Mon. Not. R. Astron. Soc. 495, 4782–4799 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Norris, J. P. & Bonnell, J. T. Short gamma-ray bursts with extended emission. Astrophys. J. 643, 266–275 (2006).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Dichiara, S. et al. Evidence of extended emission in GRB 181123B and other high-redshift short GRBs. Astrophys. J. 911, L28 (2021).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Kennicutt, J. & Robert, C. Star formation in galaxies along the Hubble sequence. Ann. Rev. Astron. Astrophys. 36, 189–232 (1998).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Chabrier, G. Galactic stellar and substellar initial mass function. Publ. Astron. Soc. Pac. 115, 763–795 (2003).

    Article 
    ADS 

    Google Scholar
     

  • Kobulnicky, H. A. & Kewley, L. J. Metallicities of 0.3<z<1.0 galaxies in the GOODS-North field. Astrophys. J. 617, 240–261 (2004).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Johnson, B. D., Leja, J., Conroy, C. & Speagle, J. S. Stellar population inference with Prospector. Astrophys. J. 254, 22 (2021).

    Article 
    CAS 

    Google Scholar
     

  • O’Connor, B. et al. A tale of two mergers: constraints on kilonova detection in two short GRBs at z ~ 0.5. Mon. Not. R. Astron. Soc. 502, 1279–1298 (2021).

    ADS 

    Google Scholar
     

  • Palmerio, J. T. et al. Are long gamma-ray bursts biased tracers of star formation? Clues from the host galaxies of the Swift/BAT6 complete sample of bright LGRBs. III. Stellar masses, star formation rates, and metallicities at z > 1. Astron. Astrophys. 623, A26 (2019).

    Article 
    CAS 

    Google Scholar
     

  • Whitaker, K. E., van Dokkum, P. G., Brammer, G. & Franx, M. The star formation mass sequence out to z = 2.5. Astrophys. J. 754, L29 (2012).

    Article 
    ADS 

    Google Scholar
     

  • Amati, L. et al. Intrinsic spectra and energetics of BeppoSAX gamma-ray bursts with known redshifts. Astron. Astrophys. 390, 81–89 (2002).

    Article 
    ADS 

    Google Scholar
     

  • O’Connor, B. et al. A structured jet explains the extreme GRB 221009a. Sci. Adv. 9, eadi1405 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kouveliotou, C. et al. Identification of two classes of gamma-ray bursts. Astrophys. J. 413, L101 (1993).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Becerra, R. L. et al. Deciphering the unusual stellar progenitor of GRB 210704A. Mon. Not. R. Astron. Soc. 522, 5204–5216 (2023).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Clocchiatti, A., Suntzeff, N. B., Covarrubias, R. & Candia, P. The ultimate light curve of SN 1998bw/GRB 980425. Astron. J. 141, 163 (2011).

    Article 
    ADS 

    Google Scholar
     

  • Srinivasaragavan, G. P. et al. A sensitive search for supernova emission associated with the extremely energetic and nearby GRB 221009A. Astrophys. J. 949, L39 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Perets, H. B. et al. A faint type of supernova from a white dwarf with a helium-rich companion. Nature 465, 322–325 (2010).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Kasliwal, M. M. et al. Rapidly decaying supernova 2010X: a candidate “.Ia” explosion. Astrophys. J. 723, L98–L102 (2010).

    Article 
    ADS 

    Google Scholar
     

  • Zhong, S.-Q., Li, L. & Dai, Z.-G. GRB 211211A: a neutron star-white dwarf merger? Astrophys. J. 947, L21 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Fryer, C. L., Woosley, S. E., Herant, M. & Davies, M. B. Merging white dwarf/black hole binaries and gamma-ray bursts. Astrophys. J. 520, 650–660 (1999).

    Article 
    ADS 

    Google Scholar
     

  • Kaltenborn, M. A. R. et al. Abundances and transients from neutron star-white dwarf mergers. Astrophys. J. 956, 71 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Bobrick, A., Zenati, Y., Perets, H. B., Davies, M. B. & Church, R. Transients from one white dwarf–neutron star/black hole mergers. Mon. Not. R. Astron. Soc. 510, 3758–3777 (2022).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Lu, W. & Quataert, E. Late-time accretion in neutron star mergers: implications for short gamma-ray bursts and kilonovae. Mon. Not. R. Astron. Soc. 522, 5848–5861 (2023).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • Gao, H., Lei, W.-H., Zou, Y.-C., Wu, X.-F. & Zhang, B. A complete reference of the analytical synchrotron external shock models of gamma-ray bursts. New Astron. Rev. 57, 141–190 (2013).

    Article 
    ADS 

    Google Scholar
     

  • Metzger, B. D. Kilonovae. Living Rev. Relativ. 23, 1 (2019).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Buchner, J. et al. X-ray spectral modelling of the AGN obscuring region in the CDFS: Bayesian model selection and catalogue. Astron. Astrophys. 564, A125 (2014).

    Article 

    Google Scholar
     

  • Mereghetti, S., Rigoselli, M., Salvaterra, R., Tiengo, A. & Pacholski, D. P. XMM-Newton and INTEGRAL observations of the bright GRB 230307A: vanishing of the local absorption and limits on the dust in the Magellanic Bridge. Astrophys. J. 956, 97 (2023).

    Article 
    ADS 

    Google Scholar
     

  • Zhang, B. & Mészáros, P. Gamma-ray bursts: progress, problems & prospects. Int. J. Mod. Phys. A 19, 2385–2472 (2004).

    Article 
    ADS 
    CAS 

    Google Scholar
     

  • [ad_2]

    Source link

  • Twisted-layer boron nitride ceramic with high deformability and strength

    [ad_1]

    Sample preparation

    The oBN nanoprecursors were prepared by the chemical vapour deposition method16,20,29; the raw materials used in the current work were trimethyl borate and ammonia. The oBN particle size ranged from 50 to 500 nm, with an average size of around 180 nm (Supplementary Fig. 1). A DR.SINTER SPS system and HIGH MULTI 10000 hot-pressing sintering device were used to sinter the precursors, respectively. For SPS sintering, a pressure of 50 MPa was applied first, followed by rapid heating to the target temperature at a rate 100 °C per min. Temperature was monitored with an on-line infrared thermometer during sintering. After 5–10 min at the target temperature, the power was cut off, and the pressure was released. The as-sintered specimens were left in the SPS until they had cooled to room temperature; then, they were taken out and polished. TS-BN ceramics can be synthesized between 1,600 and 1,800 °C by SPS. The ceramic synthesized at 1,500 °C was a composite consisting of TS-BN and residual untransformed oBN (Supplementary Fig. 5). For hot-pressing sintering, the same sintering pressure of 50 MPa was applied first, followed by gradual heating to the target temperature at a rate of 10 °C per min. The holding time was set to 5 min, and then the heating was stopped, and the pressure was released. Densities of the as-sintered specimens were measured according to the Archimedes principle.

    XRD and Raman spectroscopy

    XRD was used to characterize both the oBN nanoprecursors and the as-sintered BN ceramics, using a Rigaku diffractometer (SmartLab, Rigaku) with Cu Kα radiation (λ = 0.15418 nm). The applied voltage and current were 40 kV and 40 mA, respectively, with a step size of 0.02° at a scanning rate of 1° per min. Raman spectra were also collected at room temperature using a Horiba Jobin Yvon LabRAM system with a laser wavelength of 473 nm. The size of the laser spot was approximately 1 μm.

    TEM sample preparation

    oBN nanoparticles were dispersed in ethanol solution by ultrasonic treatment, drop-casted on to a carbon-coated copper grid and then dried before TEM observation. Sintered BN ceramics were first crushed and ground in an agate mortar; then, small nanoplates from ceramics were used to prepare TEM samples in the same way as above for oBN. In addition, thin foils were cut from as-sintered bulk samples for TEM observation using a focused ion beam (Helios 5 CX DualBeam, ThermoFisher). The foils were further milled to less than 100 nm and polished by Ar-ion milling (NanoMill; Model 1040, Fischione) to remove surface damage.

    Microstructure characterization

    We used scanning electron microscopy (Verios, ThermoFisher) to characterize the oBN nanoparticles and fracture morphology of BN ceramics. More detailed microstructure was characterized with a scanning transmission electron microscope (Talos F200X, ThermoFisher) operated at an accelerating voltage of 200 kV and a spherical-aberration-corrected scanning transmission electron microscope (Themis Z, ThermoFisher) operated at an accelerating voltage of 300 kV. HAADF images were collected by combining 20 frames from acquired series with drift correction (DCFI in Velox software, Thermo Fisher). The probe convergence angle was set to 25 mrad, and the collecting angle for HAADF was set to 65–200 mrad to eliminate the coherent scattering effect.

    First-principles calculations

    We constructed twist-layer BN structures using the Materials Visualizer module of the Materials Studio software30. Calculations were performed on the basis of DFT as implemented in the CASTEP code31. Ultrasoft pseudopotentials were used32,33. We used the local density approximation exchange-correlation functional of Ceperley and Alder parameterized by Perdew and Zunger34,35 to perform structural optimization and calculations of total energies and elastic properties. A k-point sampling36 of 0.04 × 2π Å−1 and a plane-wave cutoff of 570 eV were applied. The Broyden–Fletcher–Goldfarb–Shanno37 minimization scheme was used for geometry optimization. Structural relaxation was stopped when the total energy changes, maximum ionic displacement, stress and ionic Hellmann–Feynman force were less than 5.0 × 10−6 eV per atom, 5.0 × 10−4 Å, 0.02 GPa and 0.01 eV Å−1, respectively. The elastic moduli of the investigated structures were calculated in the linear elastic strain range. Selected calculation parameters were tested to ensure that energy convergence was less than 1 meV per atom. To validate our computational scheme, benchmark calculations were conducted for the hBN structure. The calculated lattice parameters of a = 2.49 Å and c = 6.48 Å were in good agreement with experimental values of a = 2.50 Å and c = 6.66 Å (ref. 38). The calculated bulk modulus (27.9 GPa) of hBN was in agreement with the experimental value (25.6 GPa)39.

    Deformability factor calculation

    The ability of layered vdW materials to deform without fracture can be characterized by the deformability factor Ξ = (Ec/Es)(1/Y) (in units of GPa−1)18, where Ec and Es are the cleavage energy and slipping energy, respectively, and Y is the in-plane Young’s modulus along the slip direction. The Ec/Es ratio quantifies the plasticity of the material that conforms to the criterion proposed by Rice et al.40,41. Interlayer interactions and the relative glide of the twist-stacked BN structures were simulated on the basis of DFT calculations. The slipping step was kept at 0.3 Å during the simulation. For each step, the energy of the most stable configuration was obtained by geometrically optimizing only the interlayer distance. The (001) plane uniformly slipped along the [210] direction, which is considered to be the lowest-energy sliding direction in hBN42. We obtained the energy as a function of the slip distance over the range of periodic distances. The energy difference between the slip distance at maximum energy (Emax) and no slip (E0) was used to represent the energy barrier to overcome resistance to slip, that is, Es = Emax − E0 (ref. 18). The energy difference between the infinite interlayer distance (Einf) and Emax was considered to represent the cleavage energy, Ec = Einf − Emax (ref. 18). An interlayer distance of 10 Å was used to calculate Einf, which safely ensured that there was no interlayer interaction.

    Molecular dynamics simulation

    The phase transition process from oBN to a twisted-layer structure was simulated by molecular dynamics with the large-scale atomic/molecular massively parallel simulator code43. An extended Tersoff potential was chosen to describe the interatomic interaction44; this has been widely used to investigate the microstructural evolution of hBN45,46. In this work, a 10 × 10 × 4 nm3 supercell containing a two-shell BN nano-onion at the centre was constructed. The two-shell BN nano-onion structure was constructed using the method reported in our previous work21. The outer (inner) shell corresponded to B750N750 (B460N460), and the diameter of the BN onion was 3.61 nm. Periodic boundary conditions and isothermal–isobaric (NPT) ensemble were applied in the simulations. Each supercell was first optimized with the conjugate gradient algorithm and then relaxed for 20 ps at room temperature. Following the relaxation, the supercell was compressed uniaxially along the z direction to a given pressure (6 GPa) within 200 ps and finally heated to the target temperature (1,500 K) within 2 ns. Atomic configurations were visualized and analysed with the help of the Open Visualization Tool package47. The local structural environment of the atoms was identified using the polyhedral template matching algorithm48.

    Mechanical property characterization

    Uniaxial compression tests were performed in the MTI mechanical property testing system (MTII/Fullman SEMtester 2000) at room temperature with a strain rate of 1 × 10−4 s−1. Ceramic specimens were machined into cylinders with diameter of 2.7 mm and length of 4.0 mm (length to diameter ratio: approximately 1.5). Both ends of the cylinders were polished with diamond powder of around 0.5 μm. Parallelism between the two ends was within 0.01 mm. A thin copper foil was placed between the sample and the tester to reduce stress concentration on the contact area. Thin nickel (Ni) film was deposited on the sample surface to form markers. Each compression process was recorded in situ with a digital video recorder. Sample strain was estimated by measuring the change in distances between Ni markers. We conducted at least five tests for uniaxial compressive properties on bulk samples obtained from SPS and hot-pressing sintering.

    Tensile tests were carried out at a strain rate of 1 × 10−4 s−1. The specimens were processed into I-shape with an effective tensile length of 6 mm and a rectangular cross section of 1 mm × 1.5 mm. Flexural strength was measured using the three-point bending method. The specimens were processed into cuboids with a size of 1 mm × 2 mm × 12 mm. The span length was 11 mm, and the loading rate of the indenter was set to 0.1 mm min−1. Flexural strength (σf) was calculated as follows:

    $${{\sigma }}_{{\rm{f}}}=\frac{3FL}{{2bh}^{2}},$$

    (1)

    where F is the maximum load until the specimen fractured, L is the span length, and b and h are the width and height of the specimen, respectively.

    Fracture toughness of the specimens was determined using the single-edge V-notched beam method. The specimens were processed into cuboids with a size of 1 mm × 1.5 mm × 5 mm. A straight-through V-notch with a depth of approximately 0.5 mm was cut in the specimen using a femtosecond laser (Astrella-1K-USP). The radius of the notch tip was less than 10 μm, the span length was 4 mm and the crosshead loading rate was 0.1 mm min−1. Fracture toughness (KIC) was calculated using the following equations:

    $${K}_{{\rm{I}}{\rm{C}}}=\left(\frac{FL}{B{W}^{1.5}}\right)\left\{1.5{\left(\frac{a}{W}\right)}^{0.5}Y(\frac{a}{W})\right\},$$

    (2)

    $$Y\left(\frac{a}{W}\right)=1.964-2.837\left(\frac{a}{W}\right)+13.711{\left(\frac{a}{W}\right)}^{2}-23.25{\left(\frac{a}{W}\right)}^{3}+24.129{\left(\frac{a}{W}\right)}^{4},$$

    (3)

    where F is the maximum load until the specimen fractured, L is the span length, B is the specimen width, W is the specimen height and a is the notch depth. Tests for tensile strength, flexural strength, Young’s modulus and fracture toughness were repeated at least five times.

    In situ synchrotron radiation XRD measurements

    In situ triaxial compression tests were performed using a deformation-DIA apparatus coupled with synchrotron X-rays, at the GSECARS 13-BM-D beamline of the Advanced Photon Source at the Argonne National Laboratory, USA. Details of the deformation-DIA module and the sample assembly can be found elsewhere28,49. The specimens were cylinders of 2.5 mm in diameter and 3.5 mm in length. The specimen was first compressed to a hydrostatic pressure of around 1.5 GPa; then, the differential rams were advanced to shorten the sample at a constant speed (strain rate = 1 × 10−5 s−1) at room temperature.

    The incident monochromatic beam (45 keV) was collimated to tungsten carbide (WC) slits of 200 mm × 200 mm. Detector tilt and rotation relative to the incident beam were calibrated with a CeO2 standard using the Dioptas program50. XRD patterns and radiographs of the sample were collected automatically during deformation. Exposure times for XRD and radiographs were 300 s and 10 s, respectively.

    The strain of specimen was defined as ε = (llε)/l, where l and lε are the sample lengths at the initial state and under compression, respectively. Lattice strain of the (002) and (100) reflections was defined as

    $$\frac{{d}_{{\rm{hkl}}}(\varphi ){-d}_{{\rm{P}}({\rm{hkl}})}}{{d}_{{\rm{P}}({\rm{hkl}})}}{=Q}_{{\rm{hkl}}}({1-{\rm{3cos}}}^{2}\varphi ),$$

    (4)

    where dP(hkl) is the hydrostatic pressure d-spacing, for which the right-hand side of equation (4) is zero. For each plane (hkl), d(hkl) and φ were measured from the two-dimensional diffraction pattern (with cosφ = cosθcosδ), δ being the true azimuth angle. Q(hkl) and dP(hkl) were extracted by fitting d(hkl) versus φ according to equation (4). Differential stresses σ(hkl) were calculated for planes from lattice strains Q(hkl) according to:

    $${\Delta \sigma }_{{\rm{hkl}}}{=6Q}_{{\rm{hkl}}}{G}_{{\rm{hkl}}},$$

    (5)

    where the ‘effective moduli’ Ghkl were calculated with elastic compliances Sij from inversion of the stiffness tensor (Cij) for hBN. In the current work, elastic constants of c33 = 27 GPa and c11 = 811 GPa (ref. 39) were used to calculate σ(002) and σ(100) of layered BN structures, respectively, without considering pressure effects on these moduli.

    In situ TEM nanopillar compression

    Nanopillars with diameter of around 200 nm and aspect ratio of around 2:1 from the sintered bulk ceramic were fabricated using a Ga ion beam at a voltage of 30 kV in a FEI Helios focused ion beam instrument. Initially, the samples were processed into pillars with a cross-sectional width of approximately 5 μm using relatively large currents from 21 nA to 7 nA. Subsequently, the pillars were milled to cylinders with diameter of 1 μm using low currents from 5 nA to 1 nA. Finally, the pillars were polished to the desired size of approximately 200 nm using small currents from 500 pA to 7.7 pA to minimize the damage layer.

    In situ uniaxial compression tests were performed with a Hysitron Picoindenter instrument inside a transmission electron microscope (FEI Titan ETEM G2) operated with an accelerating voltage of 300 kV. The Hysitron PI-95 holder was equipped with a diamond punch joined to a MEMS transducer. In situ compression experiments were carried out in a displacement control mode, which has been proved to be more sensitive to transient phenomena. The displacement rate was kept at 10 nm s−1 during compression, corresponding to a strain rate of 1 × 10−2 s−1. The whole process was recorded using a digital video recorder for observation of the evolution of the microstructure.

    [ad_2]

    Source link

  • Genomic data in the All of Us Research Program

    [ad_1]

    The All of Us cohort

    All of Us aims to engage a longitudinal cohort of one million or more US participants, with a focus on including populations that have historically been under-represented in biomedical research. Details of the All of Us cohort have been described previously5. Briefly, the primary objective is to build a robust research resource that can facilitate the exploration of biological, clinical, social and environmental determinants of health and disease. The programme will collect and curate health-related data and biospecimens, and these data and biospecimens will be made broadly available for research uses. Health data are obtained through the electronic medical record and through participant surveys. Survey templates can be found on our public website: https://www.researchallofus.org/data-tools/survey-explorer/. Adults 18 years and older who have the capacity to consent and reside in the USA or a US territory at present are eligible. Informed consent for all participants is conducted in person or through an eConsent platform that includes primary consent, HIPAA Authorization for Research use of EHRs and other external health data, and Consent for Return of Genomic Results. The protocol was reviewed by the Institutional Review Board (IRB) of the All of Us Research Program. The All of Us IRB follows the regulations and guidance of the NIH Office for Human Research Protections for all studies, ensuring that the rights and welfare of research participants are overseen and protected uniformly.

    Data accessibility through a ‘data passport’

    Authorization for access to participant-level data in All of Us is based on a ‘data passport’ model, through which authorized researchers do not need IRB review for each research project. The data passport is required for gaining data access to the Researcher Workbench and for creating workspaces to carry out research projects using All of Us data. At present, data passports are authorized through a six-step process that includes affiliation with an institution that has signed a Data Use and Registration Agreement, account creation, identity verification, completion of ethics training, and attestation to a data user code of conduct. Results reported follow the All of Us Data and Statistics Dissemination Policy disallowing disclosure of group counts under 20 to protect participant privacy without seeking prior approval40.

    EHR data

    At present, All of Us gathers EHR data from about 50 health care organizations that are funded to recruit and enrol participants as well as transfer EHR data for those participants who have consented to provide them. Data stewards at each provider organization harmonize their local data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model, and then submit it to the All of Us Data and Research Center (DRC) so that it can be linked with other participant data and further curated for research use. OMOP is a common data model standardizing health information from disparate EHRs to common vocabularies and organized into tables according to data domains. EHR data are updated from the recruitment sites and sent to the DRC quarterly. Updated data releases to the research community occur approximately once a year. Supplementary Table 6 outlines the OMOP concepts collected by the DRC quarterly from the recruitment sites.

    Biospecimen collection and processing

    Participants who consented to participate in All of Us donated fresh whole blood (4 ml EDTA and 10 ml EDTA) as a primary source of DNA. The All of Us Biobank managed by the Mayo Clinic extracted DNA from 4 ml EDTA whole blood, and DNA was stored at −80 °C at an average concentration of 150 ng µl−1. The buffy coat isolated from 10 ml EDTA whole blood has been used for extracting DNA in the case of initial extraction failure or absence of 4 ml EDTA whole blood. The Biobank plated 2.4 µg DNA with a concentration of 60 ng µl−1 in duplicate for array and WGS samples. The samples are distributed to All of Us Genome Centers weekly, and a negative (empty well) control and National Institute of Standards and Technology controls are incorporated every two months for QC purposes.

    Genome sequencing

    Genome Center sample receipt, accession and QC

    On receipt of DNA sample shipments, the All of Us Genome Centers carry out an inspection of the packaging and sample containers to ensure that sample integrity has not been compromised during transport and to verify that the sample containers correspond to the shipping manifest. QC of the submitted samples also includes DNA quantification, using routine procedures to confirm volume and concentration (Supplementary Table 7). Any issues or discrepancies are recorded, and affected samples are put on hold until resolved. Samples that meet quality thresholds are accessioned in the Laboratory Information Management System, and sample aliquots are prepared for library construction processing (for example, normalized with respect to concentration and volume).

    WGS library construction, sequencing and primary data QC

    The DNA sample is first sheared using a Covaris sonicator and is then size-selected using AMPure XP beads to restrict the range of library insert sizes. Using the PCR Free Kapa HyperPrep library construction kit, enzymatic steps are completed to repair the jagged ends of DNA fragments, add proper A-base segments, and ligate indexed adapter barcode sequences onto samples. Excess adaptors are removed using AMPure XP beads for a final clean-up. Libraries are quantified using quantitative PCR with the Illumina Kapa DNA Quantification Kit and then normalized and pooled for sequencing (Supplementary Table 7).

    Pooled libraries are loaded on the Illumina NovaSeq 6000 instrument. The data from the initial sequencing run are used to QC individual libraries and to remove non-conforming samples from the pipeline. The data are also used to calibrate the pooling volume of each individual library and re-pool the libraries for additional NovaSeq sequencing to reach an average coverage of 30×.

    After demultiplexing, WGS analysis occurs on the Illumina DRAGEN platform. The DRAGEN pipeline consists of highly optimized algorithms for mapping, aligning, sorting, duplicate marking and haplotype variant calling and makes use of platform features such as compression and BCL conversion. Alignment uses the GRCh38dh reference genome. QC data are collected at every stage of the analysis protocol, providing high-resolution metrics required to ensure data consistency for large-scale multiplexing. The DRAGEN pipeline produces a large number of metrics that cover lane, library, flow cell, barcode and sample-level metrics for all runs as well as assessing contamination and mapping quality. The All of Us Genome Centers use these metrics to determine pass or fail for each sample before submitting the CRAM files to the All of Us DRC. For mapping and variant calling, all Genome Centers have harmonized on a set of DRAGEN parameters, which ensures consistency in processing (Supplementary Table 2).

    Every step through the WGS procedure is rigorously controlled by predefined QC measures. Various control mechanisms and acceptance criteria were established during WGS assay validation. Specific metrics for reviewing and releasing genome data are: mean coverage (threshold of ≥30×), genome coverage (threshold of ≥90% at 20×), coverage of hereditary disease risk genes (threshold of ≥95% at 20×), aligned Q30 bases (threshold of ≥8 × 1010), contamination (threshold of ≤1%) and concordance to independently processed array data.

    Array genotyping

    Samples are processed for genotyping at three All of Us Genome Centers (Broad, Johns Hopkins University and University of Washington). DNA samples are received from the Biobank and the process is facilitated by the All of Us genomics workflow described above. All three centres used an identical array product, scanners, resource files and genotype calling software for array processing to reduce batch effects. Each centre has its own Laboratory Information Management System that manages workflow control, sample and reagent tracking, and centre-specific liquid handling robotics.

    Samples are processed using the Illumina Global Diversity Array (GDA) with Illumina Infinium LCG chemistry using the automated protocol and scanned on Illumina iSCANs with Automated Array Loaders. Illumina IAAP software converts raw data (IDAT files; 2 per sample) into a single GTC file per sample using the BPM file (defines strand, probe sequences and illumicode address) and the EGT file (defines the relationship between intensities and genotype calls). Files used for this data release are: GDA-8v1-0_A5.bpm, GDA-8v1-0_A1_ClusterFile.egt, gentrain v3, reference hg19 and gencall cutoff 0.15. The GDA array assays a total of 1,914,935 variant positions including 1,790,654 single-nucleotide variants, 44,172 indels, 9,935 intensity-only probes for CNV calling, and 70,174 duplicates (same position, different probes). Picard GtcToVcf is used to convert the GTC files to VCF format. Resulting VCF and IDAT files are submitted to the DRC for ingestion and further processing. The VCF file contains assay name, chromosome, position, genotype calls, quality score, raw and normalized intensities, B allele frequency and log R ratio values. Each genome centre is running the GDA array under Clinical Laboratory Improvement Amendments-compliant protocols. The GTC files are parsed and metrics are uploaded to in-house Laboratory Information Management System systems for QC review.

    At batch level (each set of 96-well plates run together in the laboratory at one time), each genome centre includes positive control samples that are required to have >98% call rate and >99% concordance to existing data to approve release of the batch of data. At the sample level, the call rate and sex are the key QC determinants41. Contamination is also measured using BAFRegress42 and reported out as metadata. Any sample with a call rate below 98% is repeated one time in the laboratory. Genotyped sex is determined by plotting normalized x versus normalized y intensity values for a batch of samples. Any sample discordant with ‘sex at birth’ reported by the All of Us participant is flagged for further detailed review and repeated one time in the laboratory. If several sex-discordant samples are clustered on an array or on a 96-well plate, the entire array or plate will have data production repeated. Samples identified with sex chromosome aneuploidies are also reported back as metadata (XXX, XXY, XYY and so on). A final processing status of ‘pass’, ‘fail’ or ‘abandon’ is determined before release of data to the All of Us DRC. An array sample will pass if the call rate is >98% and the genotyped sex and sex at birth are concordant (or the sex at birth is not applicable). An array sample will fail if the genotyped sex and the sex at birth are discordant. An array sample will have the status of abandon if the call rate is <98% after at least two attempts at the genome centre.

    Data from the arrays are used for participant return of genetic ancestry and non-health-related traits for those who consent, and they are also used to facilitate additional QC of the matched WGS data. Contamination is assessed in the array data to determine whether DNA re-extraction is required before WGS. Re-extraction is prompted by level of contamination combined with consent status for return of results. The arrays are also used to confirm sample identity between the WGS data and the matched array data by assessing concordance at 100 unique sites. To establish concordance, a fingerprint file of these 100 sites is provided to the Genome Centers to assess concordance with the same sites in the WGS data before CRAM submission.

    Genomic data curation

    As seen in Extended Data Fig. 2, we generate a joint call set for all WGS samples and make these data available in their entirety and by sample subsets to researchers. A breakdown of the frequencies, stratified by computed ancestries for which we had more than 10,000 participants can be found in Extended Data Fig. 3. The joint call set process allows us to leverage information across samples to improve QC and increase accuracy.

    Single-sample QC

    If a sample fails single-sample QC, it is excluded from the release and is not reported in this document. These tests detect sample swaps, cross-individual contamination and sample preparation errors. In some cases, we carry out these tests twice (at both the Genome Center and the DRC), for two reasons: to confirm internal consistency between sites; and to mark samples as passing (or failing) QC on the basis of the research pipeline criteria. The single-sample QC process accepts a higher contamination rate than the clinical pipeline (0.03 for the research pipeline versus 0.01 for the clinical pipeline), but otherwise uses identical thresholds. The list of specific QC processes, passing criteria, error modes addressed and an overview of the results can be found in Supplementary Table 3.

    Joint call set QC

    During joint calling, we carry out additional QC steps using information that is available across samples including hard thresholds, population outliers, allele-specific filters, and sensitivity and precision evaluation. Supplementary Table 4 summarizes both the steps that we took and the results obtained for the WGS data. More detailed information about the methods and specific parameters can be found in the All of Us Genomic Research Data Quality Report36.

    Batch effect analysis

    We analysed cross-sequencing centre batch effects in the joint call set. To quantify the batch effect, we calculated Cohen’s d (ref. 43) for four metrics (insertion/deletion ratio, single-nucleotide polymorphism count, indel count and single-nucleotide polymorphism transition/transversion ratio) across the three genome sequencing centres (Baylor College of Medicine, Broad Institute and University of Washington), stratified by computed ancestry and seven regions of the genome (whole genome, high-confidence calling, repetitive, GC content of >0.85, GC content of <0.15, low mappability, the ACMG59 genes and regions of large duplications (>1 kb)). Using random batches as a control set, all comparisons had a Cohen’s d of <0.35. Here we report any Cohen’s d results >0.5, which we chose before this analysis and is conventionally the threshold of a medium effect size44.

    We found that there was an effect size in indel counts (Cohen’s d of 0.53) in the entire genome, between Broad Institute and University of Washington, but this was being driven by repetitive and low-mappability regions. We found no batch effects with Cohen’s d of >0.5 in the ratio metrics or in any metrics in the high-confidence calling, low or high GC content, or ACMG59 regions. A complete list of the batch effects with Cohen’s d of >0.5 are found in Supplementary Table 8.

    Sensitivity and precision evaluation

    To determine sensitivity and precision, we included four well-characterized control samples (four National Institute of Standards and Technology Genome in a Bottle samples (HG-001, HG-003, HG-004 and HG-005). The samples were sequenced with the same protocol as All of Us. Of note, these samples were not included in data released to researchers. We used the corresponding published set of variant calls for each sample as the ground truth in our sensitivity and precision calculations. We use the high-confidence calling region, defined by Genome in a Bottle v4.2.1, as the source of ground truth. To be called a true positive, a variant must match the chromosome, position, reference allele, alternate allele and zygosity. In cases of sites with multiple alternative alleles, each alternative allele is considered separately. Sensitivity and precision results are reported in Supplementary Table 5.

    Genetic ancestry inference

    We computed categorical ancestry for all WGS samples in All of Us and made these available to researchers. These predictions are also the basis for population allele frequency calculations in the Genomic Variants section of the public Data Browser. We used the high-quality set of sites to determine an ancestry label for each sample. The ancestry categories are based on the same labels used in gnomAD18, the Human Genome Diversity Project (HGDP)45 and 1000 Genomes1: African (AFR); Latino/admixed American (AMR); East Asian (EAS); Middle Eastern (MID); European (EUR), composed of Finnish (FIN) and Non-Finnish European (NFE); Other (OTH), not belonging to one of the other ancestries or is an admixture; South Asian (SAS).

    We trained a random forest classifier46 on a training set of the HGDP and 1000 Genomes samples variants on the autosome, obtained from gnomAD11. We generated the first 16 principal components (PCs) of the training sample genotypes (using the hwe_normalized_pca in Hail) at the high-quality variant sites for use as the feature vector for each training sample. We used the truth labels from the sample metadata, which can be found alongside the VCFs. Note that we do not train the classifier on the samples labelled as Other. We use the label probabilities (‘confidence’) of the classifier on the other ancestries to determine ancestry of Other.

    To determine the ancestry of All of Us samples, we project the All of Us samples into the PCA space of the training data and apply the classifier. As a proxy for the accuracy of our All of Us predictions, we look at the concordance between the survey results and the predicted ancestry. The concordance between self-reported ethnicity and the ancestry predictions was 87.7%.

    PC data from All of Us samples and the HGDP and 1000 Genomes samples were used to compute individual participant genetic ancestry fractions for All of Us samples using the Rye program. Rye uses PC data to carry out rapid and accurate genetic ancestry inference on biobank-scale datasets47. HGDP and 1000 Genomes reference samples were used to define a set of six distinct and coherent ancestry groups—African, East Asian, European, Middle Eastern, Latino/admixed American and South Asian—corresponding to participant self-identified race and ethnicity groups. Rye was run on the first 16 PCs, using the defined reference ancestry groups to assign ancestry group fractions to individual All of Us participant samples.

    Relatedness

    We calculated the kinship score using the Hail pc_relate function and reported any pairs with a kinship score above 0.1. The kinship score is half of the fraction of the genetic material shared (ranges from 0.0 to 0.5). We determined the maximal independent set41 for related samples. We identified a maximally unrelated set of 231,442 samples (94%) for kinship scored greater than 0.1.

    LDL-C common variant GWAS

    The phenotypic data were extracted from the Curated Data Repository (CDR, Control Tier Dataset v7) in the All of Us Researcher Workbench. The All of Us Cohort Builder and Dataset Builder were used to extract all LDL cholesterol measurements from the Lab and Measurements criteria in EHR data for all participants who have WGS data. The most recent measurements were selected as the phenotype and adjusted for statin use19, age and sex. A rank-based inverse normal transformation was applied for this continuous trait to increase power and deflate type I error. Analysis was carried out on the Hail MatrixTable representation of the All of Us WGS joint-called data including removing monomorphic variants, variants with a call rate of <95% and variants with extreme Hardy–Weinberg equilibrium values (P < 10−15). A linear regression was carried out with REGENIE48 on variants with a minor allele frequency >5%, further adjusting for relatedness to the first five ancestry PCs. The final analysis included 34,924 participants and 8,589,520 variants.

    Genotype-by-phenotype replication

    We tested replication rates of known phenotype–genotype associations in three of the four largest populations: EUR, AFR and EAS. The AMR population was not included because they have no registered GWAS. This method is a conceptual extension of the original GWAS × phenome-wide association study, which replicated 66% of powered associations in a single EHR-linked biobank49. The PGRM is an expansion of this work by Bastarache et al., based on associations in the GWAS catalogue50 in June 2020 (ref. 51). After directly matching the Experimental Factor Ontology terms to phecodes, the authors identified 8,085 unique loci and 170 unique phecodes that compose the PGRM. They showed replication rates in several EHR-linked biobanks ranging from 76% to 85%. For this analysis, we used the EUR-, and AFR-based maps, considering only catalogue associations that were P < 5 × 10−8 significant.

    The main tools used were the Python package Hail for data extraction, plink for genomic associations, and the R packages PheWAS and pgrm for further analysis and visualization. The phenotypes, participant-reported sex at birth, and year of birth were extracted from the All of Us CDR (Controlled Tier Dataset v7). These phenotypes were then loaded into a plink-compatible format using the PheWAS package, and related samples were removed by sub-setting to the maximally unrelated dataset (n = 231,442). Only samples with EHR data were kept, filtered by selected loci, annotated with demographic and phenotypic information extracted from the CDR and ancestry prediction information provided by All of Us, ultimately resulting in 181,345 participants for downstream analysis. The variants in the PGRM were filtered by a minimum population-specific allele frequency of >1% or population-specific allele count of >100, leaving 4,986 variants. Results for which there were at least 20 cases in the ancestry group were included. Then, a series of Firth logistic regression tests with phecodes as the outcome and variants as the predictor were carried out, adjusting for age, sex (for non-sex-specific phenotypes) and the first three genomic PC features as covariates. The PGRM was annotated with power calculations based on the case counts and reported allele frequencies. Power of 80% or greater was considered powered for this analysis.

    Reporting summary

    Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

    [ad_2]

    Source link

  • Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

    [ad_1]

  • Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, UK

    Ken Suzuki & Andrew P. Morris

  • Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Ken Suzuki, Nobuhiro Shojima, Toshimasa Yamauchi & Takashi Kadowaki

  • Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan

    Ken Suzuki, Kyuto Sonehara, Shinichi Namba, Yukinori Okada & Kenichi Yamamoto

  • Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Konstantinos Hatzikotoulas, Lorraine Southam, Nigel W. Rayner, Ozvan Bocher, Ana Luiza Arruda, Andrew P. Morris & Eleftheria Zeggini

  • Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    Henry J. Taylor, Jacob M. Keaton, Huan Mo, Tam C. Tran, Francis S. Collins & Joshua C. Denny

  • British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

    Henry J. Taylor, Adam S. Butterworth & John Danesh

  • Heart and Lung Research Institute, University of Cambridge, Cambridge, UK

    Henry J. Taylor, Adam S. Butterworth & John Danesh

  • Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China

    Xianyong Yin

  • Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA

    Xianyong Yin, Brett Vanderwerff, Daniel Taliun, Snehal Patil, Matthew Zawistowski, Sebastian Zöllner & Michael Boehnke

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA

    Kim M. Lorenz, Kyong-Mi Chang, Marijana Vujkovic & Benjamin F. Voight

  • Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Kim M. Lorenz & Benjamin F. Voight

  • Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Kim M. Lorenz, Daniel J. Rader, Marylyn D. Ritchie & Benjamin F. Voight

  • Programs in Metabolism and Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA

    Ravi Mandla, Alicia Huerta-Chagoya, Philip Schroeder, Miriam S. Udler, Jose C. Florez, James B. Meigs & Josep M. Mercader

  • Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

    Ravi Mandla, Philip Schroeder, Varinderpal Kaur, Miriam S. Udler, Jose C. Florez & Josep M. Mercader

  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Giorgio E. M. Melloni, Frederick K. Kamanu, Filipe A. Moura, Nicholas A. Marston & Christian T. Ruff

  • William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

    Stavroula Kanoni, Ioanna Ntalla & Stavroula Kanona

  • Graduate School of Experimental Medicine, Technical University of Munich, Munich, Germany

    Ana Luiza Arruda

  • Munich School for Data Science, Helmholtz Munich, Neuherberg, Germany

    Ana Luiza Arruda

  • Department of Genome Informatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Kyuto Sonehara & Yukinori Okada

  • Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan

    Kyuto Sonehara & Yukinori Okada

  • Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

    Kyuto Sonehara & Yukinori Okada

  • Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Simon S. K. Lee, Michael H. Preuss & Ruth J. F. Loos

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Lauren E. Petty, Hannah G. Polikowsky & Jennifer E. Below

  • Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

    Mart Kals, Krista Fischer, Kristi Läll, Andres Metspalu, Reedik Mägi & Andrew P. Morris

  • Nuffield Department of Population Health, University of Oxford, Oxford, UK

    Fiona Bragg, Kuang Lin, Zhengming Chen, Iona Y. Millwood & Robin G. Walters

  • Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK

    Fiona Bragg, Zhengming Chen, Iona Y. Millwood & Robin G. Walters

  • Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

    Xiuqing Guo, Jie Yao, Yang Hai, Jingyi Tan, Katheryn Roll, Kevin Sandow, Kent D. Taylor, Yii-Der Ida Chen & Jerome I. Rotter

  • Department of Epidemiology and Biostatistics, Imperial College London, London, UK

    Weihua Zhang & John C. Chambers

  • Department of Cardiology, Ealing Hospital, London NorthWest Healthcare NHS Trust, London, UK

    Weihua Zhang, Jaspal S. Kooner & John C. Chambers

  • Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju-si, South Korea

    Young Jin Kim, Sanghoon Moon & Sohee Han

  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Mariaelisa Graff, Rebecca Rohde & Kari E. North

  • Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

    Fumihiko Takeuchi, Masato Isono & Norihiro Kato

  • Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Jana Nano, Christian Gieger, Annette Peters, Barbara Thorand & Harald Grallert

  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Amel Lamri, Sonia S. Anand, Hertzel C. Gerstein & Salim Yusuf

  • Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada

    Amel Lamri, Sonia S. Anand, Hertzel C. Gerstein, Salim Yusuf & Guillaume Paré

  • Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Masahiro Nakatochi

  • MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK

    Robert A. Scott, Alice Williamson, Jian’an Luan, Eleanor Wheeler, Nicholas J. Wareham & Claudia Langenberg

  • Department of Health Data Science, University of Liverpool, Liverpool, UK

    James P. Cook

  • Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, USA

    Jung-Jin Lee

  • Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA

    Ian Pan, Mengna Huang & Simin Liu

  • Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario, Canada

    Esteban J. Parra

  • Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore

    Jin-Fang Chai, Victor J. Y. Lim, Rob M. van Dam, E-Shyong Tai & Xueling Sim

  • Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA

    Lawrence F. Bielak, Jennifer A. Smith, Sharon L. R. Kardia & Patricia A. Peyser

  • Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Yasuharu Tabara, Takahisa Kawaguchi & Fumihiko Matsuda

  • deCODE Genetics, Amgen, Reykjavik, Iceland

    Gudmar Thorleifsson, Valgerdur Steinthorsdottir, Unnur Thorsteinsdottir & Kari Stefansson

  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Niels Grarup, Jette Bork-Jensen, Torben Hansen, Oluf Pedersen & Ruth J. F. Loos

  • Department of Biostatistics, Harvard University, Boston, MA, USA

    Tamar Sofer

  • Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, MA, USA

    Tamar Sofer, Brian E. Cade & Susan Redline

  • Department of Medicine, Harvard University, Boston, MA, USA

    Tamar Sofer

  • Institute of Genetic Epidemiology, Department of Data Driven Medicine, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany

    Matthias Wuttke & Anna Köttgen

  • Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA

    Chloé Sarnowski

  • German Center for Diabetes Research (DZD), Neuherberg, Germany

    Christian Gieger, Christian Herder, Annette Peters, Michael Roden, Barbara Thorand & Harald Grallert

  • Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Christian Gieger

  • Department of Population and Public Health Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA

    Darryl Nousome & Roberta McKean-Cowdin

  • Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

    Stella Trompet & J. Wouter Jukema

  • Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands

    Stella Trompet & Raymond Noordam

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Soo-Heon Kwak & Kyong-Soo Park

  • Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA

    Jirong Long, Edmond Kabagambe, Jacob M. Keaton, Wei Zheng & Xiao-Ou Shu

  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

    Meng Sun

  • Institute for Population and Precision Health (IPPH), Biological Sciences Division, University of Chicago, Chicago, IL, USA

    Lin Tong, Farzana Jasmine, Muhammad G. Kibriya, Mohammad Shahriar & Habibul Ahsan

  • Department of Public Health Sciences and Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA

    Wei-Min Chen, Uma Nayak & Michèle M. Sale

  • Genomic Research on Complex Diseases (GRC-Group), CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, India

    Suraj S. Nongmaithem, Sohail Rafik Mansuri, Alagu Sankareswaran & Giriraj R. Chandak

  • Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China

    Claudia H. T. Tam, Juliana C. N. Chan, Guozhi Jiang, Andrea O. Luk, Wing Yee So, Brian Tomlinson & Ronald C. W. Ma

  • Chinese University of Hong Kong–Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine, Chinese University of Hong Kong, Hong Kong, China

    Claudia H. T. Tam, Juliana C. N. Chan, Guozhi Jiang, Andrea O. Luk & Ronald C. W. Ma

  • Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea

    Yoonjung Yoonie Joo

  • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Yoonjung Yoonie Joo & Laura J. Rasmussen-Torvik

  • Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

    Chien-Hsiun Chen, Li-Ching Chang, Yuan-Tsong Chen & Jer-Yuarn Wu

  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Laura M. Raffield, K. Alaine Broadaway, Qing Duan, Yun Li & Karen L. Mohlke

  • Department of Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK

    Bram Peter Prins, John Danesh & Sophie Hackinger

  • Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

    Aude Nicolas & Michael A. Nalls

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Lisa R. Yanek & Diane M. Becker

  • Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    Guanjie Chen, Adebowale Adeyemo, Ayo P. Doumatey & Charles N. Rotimi

  • Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA

    Jennifer A. Brody, James S. Floyd & Bruce M. Psaty

  • Division of Academics, Ochsner Health, New Orleans, LA, USA

    Edmond Kabagambe

  • Division of Statistical Genomics, Washington University School of Medicine, St Louis, MO, USA

    Ping An & Michael A. Province

  • Department of Research and Evaluation, Division of Biostatistics Research, Kaiser Permanente of Southern California, Pasadena, CA, USA

    Anny H. Xiang

  • Department of Biomedical Science, Hallym University, Chuncheon, South Korea

    Hyeok Sun Choi & Yoon Shin Cho

  • Harvard Medical School, Boston, MA, USA

    Brian E. Cade, Susan Redline & Josep M. Mercader

  • Metabolic Research Laboratories, Wellcome Trust–Medical Research Council Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK

    Alice Williamson

  • Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

    Zoha Kamali

  • Department of Bioinformatics, Isfahan University of Medical Sciences, Isfahan, Iran

    Zoha Kamali

  • Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Jinrui Cui & Mark O. Goodarzi

  • Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden

    Manonanthini Thangam, Olle Melander, Tiinamaija Tuomi & Emma Ahlqvist

  • Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Linda S. Adair, Shufa Du & Penny Gordon-Larsen

  • Unidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Carlos A. Aguilar-Salinas

  • Steno Diabetes Center Copenhagen, Herlev, Denmark

    Tarunveer S. Ahluwalia

  • Bioinformatics Center, Department of Biology, University of Copenhagen, Copenhagen, Denmark

    Tarunveer S. Ahluwalia

  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

    Sonia S. Anand, Hertzel C. Gerstein & Salim Yusuf

  • Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Alain Bertoni & Yongmei Liu

  • Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark

    Ivan Brandslund

  • Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark

    Ivan Brandslund

  • Department of Medicine, Division of Endocrinology and Diabetes, Keck School of Medicine of USC, Los Angeles, CA, USA

    Thomas A. Buchanan

  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    Charles F. Burant

  • British Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK

    Adam S. Butterworth & John Danesh

  • Health Data Research UK Cambridge, Wellcome Genome Campus, University of Cambridge, Hinxton, UK

    Adam S. Butterworth & John Danesh

  • National Institute for Health and Care Research (NIHR) Blood and Transplant Unit (BTRU) in Donor Health and Behaviour, Heart and Lung Research Institute, University of Cambridge, Cambridge, UK

    Adam S. Butterworth & John Danesh

  • Inserm U1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France

    Mickaël Canouil, Amélie Bonnefond & Philippe Froguel

  • University of Lille, Lille, France

    Mickaël Canouil, Amélie Bonnefond & Philippe Froguel

  • Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China

    Juliana C. N. Chan & Ronald C. W. Ma

  • Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong, Hong Kong, China

    Juliana C. N. Chan, Wing Yee So & Ronald C. W. Ma

  • Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore

    Miao-Li Chee, Charumathi Sabanayagam, Liang Zhang, Tien-Yin Wong & Ching-Yu Cheng

  • Exeter Centre of Excellence in Diabetes (ExCEeD), Exeter Medical School, University of Exeter, Exeter, UK

    Ji Chen

  • Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK

    Ji Chen

  • Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Shyh-Huei Chen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

    Lee-Ming Chuang

  • Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan

    Lee-Ming Chuang

  • Department of Medicine, University of Vermont, Colchester, VT, USA

    Mary Cushman

  • Section of Endocrinology and Metabolism, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Swapan K. Das

  • Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka

    H. Janaka de Silva

  • Department of Nutrition and Dietetics, Harokopio University of Athens, Athens, Greece

    George Dedoussis

  • Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Latchezar Dimitrov, Jacob M. Keaton, Donald W. Bowden & Maggie C. Y. Ng

  • Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Shufa Du, Penny Gordon-Larsen & Annie-Green Howard

  • Department of Nephrology and Medical Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany

    Kai-Uwe Eckardt

  • Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Kai-Uwe Eckardt

  • Department of Biostatistics, University of Washington, Seattle, WA, USA

    Leslie S. Emery, Tin Louie & Adrienne M. Stilp

  • California Pacific Medical Center Research Institute, San Francisco, CA, USA

    Daniel S. Evans

  • Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA

    Michele K. Evans, Botong Shen & Alan B. Zonderman

  • Institute of Mathematics and Statistics, University of Tartu, Tartu, Estonia

    Krista Fischer

  • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

    Ian Ford

  • Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

    Oscar H. Franco, Mohammad Arfan Ikram, Symen Ligthart & Mohsen Ghanbari

  • Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK

    Timothy M. Frayling

  • Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Barry I. Freedman

  • Department of Medicine, Division of Endocrinology and Metabolism, Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA

    Pauline Genter & Eli Ipp

  • Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

    Vilmantas Giedraitis & Martin Ingelsson

  • Centro de Estudios en Diabetes, Unidad de Investigacion en Diabetes y Riesgo Cardiovascular, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Mexico City, Mexico

    Clicerio González-Villalpando & Maria Elena González-Villalpando

  • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

    Myron Gross

  • Genomics and Computational Biology Graduate Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Lindsay A. Guare

  • Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

    Liisa Hakaste & Tiinamaija Tuomi

  • Folkhalsan Research Center, Helsinki, Finland

    Liisa Hakaste & Tiinamaija Tuomi

  • University of Exeter Medical School, University of Exeter, Exeter, UK

    Andrew T. Hattersley

  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    Christian Herder & Michael Roden

  • Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    Christian Herder & Michael Roden

  • Laboratory for Genomics of Diabetes and Metabolism, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

    Momoko Horikoshi & Shiro Maeda

  • Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Annie-Green Howard

  • Department of Internal Medicine, Diabetes and Metabolism Research Center, Ohio State University Wexner Medical Center, Columbus, OH, USA

    Willa Hsueh

  • Center for Global Cardiometabolic Health, Brown University, Providence, RI, USA

    Mengna Huang & Simin Liu

  • Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China

    Wei Huang & Jinxiu Shi

  • Division of Endocrine and Metabolism, Tri-Service General Hospital Songshan Branch, Taipei, Taiwan

    Yi-Jen Hung

  • School of Medicine, National Defense Medical Center, Taipei, Taiwan

    Yi-Jen Hung & Wayne H. H. Sheu

  • Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju-si, Korea

    Mi Yeong Hwang, Hye-Mi Jang, Dong Mun Shin, Kyungheon Yoon, Juyoung Lee & Bong-Jo Kim

  • Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Chii-Min Hwu

  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

    Chii-Min Hwu & Wayne H. H. Sheu

  • Department of Environmental and Preventive Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan

    Sahoko Ichihara

  • University of Chicago Research Bangladesh, Dhaka, Bangladesh

    Md. Tariqul Islam

  • Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland

    Jost B. Jonas

  • Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark

    Torben Jørgensen & Allan Linneberg

  • Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Torben Jørgensen

  • Faculty of Medicine, Aalborg University, Aalborg, Denmark

    Torben Jørgensen

  • Department of Clinical Diabetes, Endocrinology and Metabolism, Department of Translational Research and Cellular Therapeutics, City of Hope, Duarte, CA, USA

    Fouad R. Kandeel

  • Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka

    Anuradhani Kasturiratne & Ananda R. Wickremasinghe

  • Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan

    Tomohiro Katsuya

  • Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan

    Tomohiro Katsuya

  • Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Abel N. Kho

  • Center for Health Information Partnerships, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Abel N. Kho

  • Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore

    Chiea-Chuen Khor & Jianjun Liu

  • Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea

    Duk-Hwan Kim

  • Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria

    Florian Kronenberg & Sebastian Schönherr

  • Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

    Johanna Kuusisto, Alena Stančáková & Markku Laakso

  • Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

    Leslie A. Lange

  • VA Salt Lake City Health Care System, Salt Lake City, UT, USA

    Kyung Min Lee & Julie A. Lynch

  • Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

    Kyung Min Lee & Julie A. Lynch

  • Soochunhyang Institute of Medi-bio Science and Division of Endocrinology, Department of Internal Medicine, Soochunhyang University College of Medicine, Cheonan, South Korea

    Myung-Shik Lee

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Myung-Shik Lee

  • USC-Office of Population Studies Foundation, University of San Carlos, Cebu City, Philippines

    Nanette R. Lee

  • Department of Medicine, Harvard Medical School, Boston, MA, USA

    Aaron Leong, Miriam S. Udler, Jose C. Florez & James B. Meigs

  • Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA

    Aaron Leong, Bianca Porneala & James B. Meigs

  • Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

    Liming Li, Jun Lv & Canqing Yu

  • Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China

    Liming Li, Jun Lv, Pei Pei & Canqing Yu

  • Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

    Ruifang Li-Gao & Dennis O. Mook-Kanamori

  • Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

    Cecilia M. Lindgren, Mark I. McCarthy & Anubha Mahajan

  • Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA

    Cecilia M. Lindgren

  • Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK

    Cecilia M. Lindgren

  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Allan Linneberg

  • Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

    Ching-Ti Liu & Josee Dupuis

  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore

    Jianjun Liu, Rob M. van Dam & E-Shyong Tai

  • McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA

    Adam E. Locke

  • Department of Medicine, Division of Genomics and Bioinformatics, Washington University School of Medicine, St Louis, MO, USA

    Adam E. Locke

  • Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA

    Xi Luo

  • Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden

    Valeriya Lyssenko

  • Department of Clinical Science, Center for Diabetes Research, University of Bergen, Bergen, Norway

    Valeriya Lyssenko

  • Department of Advanced Genomic and Laboratory Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan

    Shiro Maeda

  • Division of Clinical Laboratory and Blood Transfusion, University of the Ryukyus Hospital, Nishihara, Japan

    Shiro Maeda

  • Dromokaiteio Psychiatric Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Vasiliki Mamakou

  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India

    Sohail Rafik Mansuri & Alagu Sankareswaran

  • Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

    Koichi Matsuda

  • Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

    Thomas Meitinger

  • Institute of Human Genetics, Technical University Munich, Munich, Germany

    Thomas Meitinger

  • German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany

    Thomas Meitinger & Annette Peters

  • Usher Institute to the Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

    Andrew D. Morris

  • Department of Medicine and Pharmacology, New York Medical College, Valhalla, NY, USA

    Jerry L. Nadler

  • Data Tecnica International, Glen Echo, MD, USA

    Michael A. Nalls

  • Center for Alzheimer’s and Related Dementias, National Institutes of Health, Bethesda, MD, USA

    Michael A. Nalls

  • Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan

    Yukinori Okada & Kenichi Yamamoto

  • Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Japan

    Yukinori Okada

  • Instituto Nacional de Medicina Genómica, Mexico City, Mexico

    Lorena Orozco

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Sanjay R. Patel

  • Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA

    Mark A. Pereira & James S. Pankow

  • Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany

    Annette Peters

  • Department of Diabetes and Endocrinology, Nelson R. Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

    Fraser J. Pirie & Ayesha A. Motala

  • Academy of Scientific and Innovative Research, CSIR-Human Resource Development Campus, Ghaziabad, India

    Gauri Prasad

  • Genomics and Molecular Medicine Unit, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India

    Gauri Prasad

  • Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Alexander P. Reiner & Charles Kooperberg

  • Ophthalmology and Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore

    Charumathi Sabanayagam, Tien-Yin Wong & Ching-Yu Cheng

  • Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore

    Charumathi Sabanayagam, Tien-Yin Wong & Ching-Yu Cheng

  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK

    Naveed Sattar

  • Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA

    Jennifer A. Smith

  • Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany

    Konstantin Strauch

  • Institute for Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University, Mainz, Germany

    Konstantin Strauch

  • Chair of Genetic Epidemiology, Institute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany

    Konstantin Strauch

  • Faculty of Medicine, University of Iceland, Reykjavik, Iceland

    Unnur Thorsteinsdottir & Kari Stefansson

  • Faculty of Medicine, Macau University of Science and Technology, Macau, China

    Brian Tomlinson

  • Department of Medical Genetics and Medical Research, China Medical University Hospital, Taichung, Taiwan

    Fuu-Jen Tsai

  • Population Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland

    Jaakko Tuomilehto

  • National School of Public Health, Madrid, Spain

    Jaakko Tuomilehto

  • Department of Public Health, University of Helsinki, Helsinki, Finland

    Jaakko Tuomilehto

  • Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia

    Jaakko Tuomilehto

  • Unidad de Biología Molecular y Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Teresa Tusie-Luna

  • Departamento de Medicina Genómica y Toxiología Ambiental, Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico

    Teresa Tusie-Luna

  • Unidad de Investigacion Medica en Bioquimica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

    Adan Valladares-Salgado & Miguel Cruz

  • Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

    Jan B. van Klinken & Ko Willems van Dijk

  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

    Jan B. van Klinken & Ko Willems van Dijk

  • Department of Clinical Chemistry, Laboratory of Genetic Metabolic Disease, Amsterdam University Medical Center, Amsterdam, The Netherlands

    Jan B. van Klinken

  • Southern California Eye Institute, CHA Hollywood Presbyterian Hospital, Los Angeles, CA, USA

    Rohit Varma

  • Unidad de Investigación Médica en Epidemiologia Clinica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

    Niels Wacher-Rodarte

  • Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands

    Ko Willems van Dijk

  • Department of Public Health, Aarhus University, Aarhus, Denmark

    Daniel R. Witte

  • Danish Diabetes Academy, Odense, Denmark

    Daniel R. Witte

  • Diabetology Research Centre, King Edward Memorial Hospital and Research Centre, Pune, India

    Chittaranjan S. Yajnik

  • Department of Medical Biochemistry, Kurume University School of Medicine, Kurume, Japan

    Ken Yamamoto

  • Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan

    Kenichi Yamamoto

  • Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

    Jian-Min Yuan

  • Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

    Jian-Min Yuan

  • Department of Pediatrics, Division of Genetic and Genomic Medicine, UCI Irvine School of Medicine, Irvine, CA, USA

    Leslie J. Raffel

  • Department of Anti-Aging Medicine, Ehime University Graduate School of Medicine, Touon, Japan

    Michiya Igase

  • Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Susan Redline

  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden

    Lars Lind

  • Institute of Molecular Medicine, University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA

    Myriam Fornage

  • Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA

    Craig L. Hanis

  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Erik Ingelsson & Philip S. Tsao

  • Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

    Erik Ingelsson

  • Department of Epidemiology, University of Washington, Seattle, WA, USA

    Bruce M. Psaty

  • Department of Health Systems and Population Health, University of Washington, Seattle, WA, USA

    Bruce M. Psaty

  • Beijing Institute of Ophthalmology, Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing, China

    Ya-Xing Wang

  • Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA

    Yongmei Liu

  • Kurume University School of Medicine, Kurume, Japan

    Mitsuhiro Yokota

  • Department of Medicine, McGill University, Montreal, Quebec, Canada

    James C. Engert

  • Department of Human Genetics, McGill University, Montreal, Quebec, Canada

    James C. Engert

  • Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

    Amélie Bonnefond & Philippe Froguel

  • Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

    James G. Wilson

  • Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

    Wayne H. H. Sheu

  • Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    M. Geoffrey Hayes

  • Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    M. Geoffrey Hayes

  • Department of Anthropology, Northwestern University, Evanston, IL, USA

    M. Geoffrey Hayes

  • Department of Endocrinology, Helsinki University Hospital, Helsinki, Finland

    Tiinamaija Tuomi

  • Science and Engineering Research Board (SERB), Department of Science and Technology, Ministry of Science and Technology, Government of India, New Delhi, India

    Giriraj R. Chandak

  • Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

    Dwaipayan Bharadwaj

  • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

    Guillaume Paré

  • Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea

    Kyong-Soo Park

  • Netherlands Heart Institute, Utrecht, The Netherlands

    J. Wouter Jukema

  • Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA

    Stephen S. Rich

  • Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany

    Harald Grallert

  • Duke-NUS Medical School, Singapore, Singapore

    E-Shyong Tai

  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

    Josee Dupuis

  • Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore, Singapore

    Woon-Puay Koh

  • Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Woon-Puay Koh

  • Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Donald W. Bowden

  • Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Donald W. Bowden & Maggie C. Y. Ng

  • Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, University of Dundee, Dundee, UK

    Colin N. A. Palmer

  • Imperial College Healthcare NHS Trust, Imperial College London, London, UK

    Jaspal S. Kooner & John C. Chambers

  • MRC-PHE Centre for Environment and Health, Imperial College London, London, UK

    Jaspal S. Kooner

  • National Heart and Lung Institute, Imperial College London, London, UK

    Jaspal S. Kooner

  • Department of Medicine, Brown University Alpert School of Medicine, Providence, RI, USA

    Simin Liu

  • Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA

    Danish Saleheen

  • Department of Cardiology, Columbia University Irving Medical Center, New York, NY, USA

    Danish Saleheen

  • Center for Non-Communicable Diseases, Karachi, Pakistan

    Danish Saleheen

  • Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin, Berlin, Germany

    Claudia Langenberg

  • Precision Healthcare University Research Institute, Queen Mary University of London, London, UK

    Claudia Langenberg

  • Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA

    Christopher A. Haiman

  • The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA

    Ruth J. F. Loos

  • Division of Translational Medicine and Therapeutics, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Daniel J. Rader

  • Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Daniel J. Rader & Benjamin F. Voight

  • Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Daniel J. Rader

  • Center for Precision Medicine, University of Pennsylvania – Perelman School of Medicine, Philadelphia, PA, USA

    Marylyn D. Ritchie

  • Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Marylyn D. Ritchie

  • Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA

    Sebastian Zöllner

  • Blizard Institute, Queen Mary University of London, London, UK

    David A. van Heel & David A. van Heel

  • Institute for Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

    Sarah Finer

  • All of Us Research Program, National Institutes of Health, Bethesda, MD, USA

    Joshua C. Denny

  • Toranomon Hospital, Tokyo, Japan

    Takashi Kadowaki

  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

    John C. Chambers

  • Vanderbilt Genetics Institute, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Maggie C. Y. Ng

  • VA Palo Alto Health Care System, Palo Alto, CA, USA

    Philip S. Tsao

  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

    Philip S. Tsao

  • Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Kyong-Mi Chang & Marijana Vujkovic

  • Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

    Mark I. McCarthy & Anubha Mahajan

  • Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

    Mark I. McCarthy

  • Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA

    Cassandra N. Spracklen

  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Marijana Vujkovic

  • TUM School of Medicine and Health, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany

    Eleftheria Zeggini

  • Central analysis group: K. Suzuki, K.H., L.S., H.J.T., X.Y., K. M. Lorenz, R. Mandla, A.H.-C., N.W.R., O.B., A.L.A., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. PS analysis: K. Suzuki, K.H., L.S., H.J.T., G.E.M.M., S.K., A.P.M. Study-level primary analysis: K. Suzuki, H.J.T., X.Y., K. M. Lorenz, R. Mandla, A.H.-C., K. Sonehara, S.N., S.S.K.L., M.H.P., L.E.P., P.S., B.V., M.K., F.B., K. Lin, X.G., W. Zhang, J.Y., Y.J.K., M. Graff, F.T., J.N., A. Lamri, M.N., S. Moon, R.A.S., J.P.C., J.-J.L., I.P., D.T., E.J.P., J.-F.C., L.F.B., Y.T., Y.H., G.T., N.G., T.S., M.W., C. Sarnowski, C.G., D.N., S.T., S.-H.K., J. Long, M. Sun, L.T., W.-M.C., S.S.N., R.N., V.J.Y.L., C.H.T.T., Y.Y.J., C.-H.C., L.M.R., B.P.P., A.N., L.R.Y., G.C., J.A.B., E.K., P.A., A.H.X., H.S.C., B.E.C., J. Tan, M.C.Y.N., X.S., A. Mahajan, C.N.S., A.P.M. Study-level sample collection, phenotyping, genotyping, and additional analysis: L.S.A., A.A., C.A.A.-S., T.S.A., S.S.A., A. Bertoni, J.B.-J., I.B., T.A.B., C.F.B., A.S.B., M. Canouil, J.C.N.C., L.-C.C., M.-L.C., J. Chen, S.-H.C., Y.-T.C., Z.C., L.-M.C., M. Cushman, J. Danesh, S.K.D., H.J.d.S., G.D., L.D., A.P.D., S.D., Q.D., K.-U.E., L.S.E., D.S.E., M.K.E., K.F., J.S.F., I.F., O.H.F., T.M.F., B.I.F., P.G., H.C.G., V.G., C.G.-V., M.E.G.-V., P.G.-L., M. Gross, L.A.G., S. Hackinger, S. Han, A.T.H., C.H., M. Horikoshi, A.-G.H., W. Hsueh, M. Huang, W. Huang, Y.-J.H., M.Y.H., C.-M.H., S.I., M.A.I., M. Ingelsson, M.T.I., M. Isono, H.-M.J., F.J., G.J., J.B.J., T.J., F.K.K., F.R.K., A. Kasturiratne, T. Katsuya, V.K., T. Kawaguchi, J.M.K., A.N.K., C.-C.K., M.G.K., D.-H.K., F.K., J.K., K. Läll, L.A.L., K.M. Lee, M.-S.L., N.R.L., A. Leong, L. Li, Y. Liu, R.L.-G., S. Lithgart, C.M.L., A. Linneberg, C.-T.L., J. Liu, A.E.L., T.L., J. Luan, A.O.L., X.L., J.Lv, J.A.L., V.L., S. Maeda, V.M., S.R.M., K.M., T.M., A. Metspalu, H.M., A.D.M., F.A.M., J.L.N., M.A.N., U.N., I.N., Y.O., L.O., S.R.P., S.P., P.P., M.A. Pereira, A.P., F.J.P., H.G.P., B.P., G. Prasad, L.J.R.-T., A.P.R., M.R., R.R., K.R., C. Sabanayagam, K. Sandow, A. Sankareswaran, N. Sattar, S.S., M. Shahriar, B.S., J.S., D.M.S., N. Shojima, J.A.S., W.Y.S., A. Stančáková, V.S., A.M.S., K. Strauch, K.D.T., B. Thorand, U.T., B. Tomlinson, T.C.T., F.-J.T., J. Tuomilehto, T.T.-L., M.S.U., A.V., R.M.v.D., J.B.v.K., R.V., N.W.-R., E.W., A.R.W., K.W.v.D., D.R.W., C.S.Y., Ken Yamamoto, Kenichi Yamamoto, K. Yoon, C.Y., J.-M.Y., S.Y., M.Z., L.Z., W. Zheng, J.S.P., T.-Y.W., F.S.C., M.O.G., K.L.M., J.C.F., J.E.B., M.I.M., M.V. Study-level principal investigator: L.J.R., M. Igase, E. Ipp, S.R., Y.S.C., L. Lind, M. A. Province, M.F., C.L.H., E. Ingelsson, A.B.Z., B.M.P., Y.-X.W., C.N.R., D.M.B., F.M., Y. Liu, M.Y., S.L.R.K., P.A.P., J.S.P., J.C.E., A. Bonnefond, P.F., J.G.W., W.H.H.S., J.-Y.W., M.G.H., R.C.W.M., T.-Y.W., D.O.M.-K., T.T., G.R.C., F.S.C., D.B., G. Paré, M.M.S., H.A., A.A.M., X.-O.S., K.-S.P., J.W.J., M. Cruz, Y.-D.I.C., S.S.R., R.M.-C., H.G., C.-Y.C., M.G., E.-S.T., J. Dupuis, N.K., M.L., A. Köttgen, W.-P.K., D.W.B., C.N.A.P., J.S.K., C.K., S. Liu, K.E.N., D.S., T.H., O.P., N.J.W., J. Lee, B.-J.K., I.Y.M., R.G.W., K. Stefansson, K.L.M., C.L., C.A.H., R.J.F.L., J.C.F., D.J.R., M.D.R., S.Z., R. Mägi, N.A.M., C.T.R., D.A.v.H., S.F., J.C.D., T.Y., T. Kadowaki, J.C.C., J.E.B., P.S.T., K.-M.C., M.I.M., J.B.M., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. MAGIC analysis: K.A.B., A.W., K.L.M., C.L. ICBP analysis: Z.K. GUARDIAN Consortium analysis: J. Cui, M.O.G. GLP-1 GWAS analysis: M.T., L.H., O.M., T.T., E.A. DIAMANTE Consortium ancestry-specific data co-ordination: J.C.C., M.C.Y.N., X.S., J.E.B., A. Mahajan. Manuscript preparation: K. Suzuki, K.H., L.S., H.J.T., X.Y., K. M. Lorenz, R. Mandla, M.I.M., J.B.M., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z. T2DGGI steering group: M.I.M., J.B.M., A. Mahajan, C.N.S., J.M.M., M.B., J.I.R., M.V., B.F.V., A.P.M., E.Z.

    [ad_2]

    Source link

  • Autonomous transposons tune their sequences to ensure somatic suppression

    [ad_1]

    Cell culture and generation of stable cell lines

    Flp-In T-REx HEK293 (Thermo Fisher Scientific, catalogue no. R78007) cells were maintained according to the manufacturer’s recommendations. Cells were cultured in DMEM with glutamax supplemented by Na-Pyruvate and High Glucose (Thermo Fisher Scientific, catalogue no. 31966-021) in the presence of 10% fetal bovine serum (FBS; Thermo Fisher Scientific, catalogue no. 10270106) and penicillin/streptomycin (Thermo Fisher Scientific, catalogue no. 15140-122). Before their introduction, transgene cells were cultured at a final concentration of 100 µg ml−1 zeocin (Thermo Fisher Scientific, catalogue no. R250-01) and 15 µg ml−1 blasticidin (Thermo Fisher Scientific, catalogue no. A1113903). For generation of stable cell lines, pOG44 (Thermo Fisher Scientific, catalogue no. V600520) was cotransfected with pcDNA5/FRT/TO (Thermo Fisher Scientific, catalogue no. V652020) containing the gene of interest at a 9:1 ratio. Cells were transfected with Lipofectamine 2000 (Thermo Fisher Scientific, catalogue no. 11668019) on a six-well-plate format with 1 µg of DNA (that is, 900 ng of pOG44 and 100 ng of pcDNA5/FRT/TO + GOI) according to the transfection protocol provided by the manufacturer. All transgenes were cloned with an N-terminal His6-biotinylation sequence-His6 tandem (HBH) tag that allows rapid and ultraclean purification without the use of antibodies. We also added a 3× FLAG tag immediately before the HBH tag to increase the versatility of the construct, which we refer to as the 3FHBH tag. Twenty-four hours following transfection, cells were split among three wells of a six-well plate at dilution ratios of 1:6, 2:6 and 3:6 to allow efficient selection of hygromycin B (Thermo Fisher Scientific, catalogue no. 10687010). Hygromycin selection was started 48 h following the transfection time point, with a final concentration of 150 µg ml−1, and refreshed every 3–4 days until control, non-transfected cells on a separate plate were totally dead. Induction of the transgene was performed overnight at a final concentration of 0.1 µg ml−1 doxycycline (DOX). Cells were validated by immunoblotting of whole-cell lysates.

    An endogenous biotin acceptor peptide affinity tag and a FLAG tag were inserted into the Safb gene locus for mouse and fly cell lines using CRISPaint. The mouse Flp-In 3T3 cell line was purchased from Thermo Fisher Scientific (catalogue no. R76107) and cultured according to the manufacturer’s instructions. Vells were cultured in DMEM (Thermo Fisher Scientific, catalogue no. 31966-021) in the presence of 10% FBS (Thermo Fisher Scientific, catalogue no. 10270106) and penicillin/streptomycin (Thermo Fisher Scientific, catalogue no. 15140-122). The Drosophila S2R+ -MT::Cas9 cell line was purchased from DGRC (DGRC stock no. 268) and cultured in S2 medium (Thermo Fisher Scientific, catalogue no. 21720024) in the presence of 10% FBS (Thermo Fisher Scientific, catalogue no. 10270106). For CRISPaint56 constructs (see Supplementary Table 2 for a list of single-guide RNAs), cells were cotransfected with three plasmids according to the CRISPaint protocol on the six-well-plate format using FuGene HD (Promega, catalogue no. E2311). Twenty-four hours following transfection, cells were expanded on 10 cm culture plates to facilitate efficient selection of puromycin (Thermo Fisher Scientific, catalogue no. A1113803). Puromycin selection is provided in the tag construct and is driven by expression from the gene locus (in this case, either the mouse or fly Safb1 gene locus). Puromycin selection was started 48 h following transfection, at 1 µg ml−1 final concentration, and was refreshed every 2 days and, in total, was maintained until all untransfected 3T3 or S2 cells were dead. Cells were validated by immunoblotting of whole-cell lysates.

    The HeLa cell line (ACC57) was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen and maintained in the same medium as the Flp-In 3T3 cell line, but with the addition of non-essential amino acids (Thermo Fisher Scientific, catalogue no. 11140050).

    Mouse N2A cells were maintained in DMEM, and stably expressing 3× FLAG-Cas9 or 3× FLAG-SAFB1 (Extended Data Fig. 10g) was created by cotransfection of cells with plasmids expressing the protein of interest (Cas9, SAFB1 or control) under the EF1alpha promoter flanked by PiggyBack inverted repeats, together with a plasmid expressing PiggyBac transposase. In this design, because neomycin resistance was coupled to transgene expression via an IRES element, cells were selected with 1 mg ml−1 geneticin until none remained in control transfected cells.

    Cell lines (human Flp-In T-REx HEK293, human HeLa, human HCT116, mouse Flp-In 3T3, mouse N2A and fly S2R+) were all purchased from vendors or repositories or provided by colleagues (as described above), and no further authentication of cell lines was performed following purchase. Routine mycoplasma contamination tests were performed on all cell lines using the Jena Biosciences Mycoplasma (PCR-based) detection kit (Jena Biosciences, no. PP-401).

    FLASH

    Cells on 15 cm dishes were washed with 6 ml of ice-cold PBS and UV-crosslinked with 0.199 mJ cm2 UV-C light, after which they were pelleted, snap-frozen in liquid nitrogen and stored at −80 °C until use. Pellets were resuspended in 600 µl of 1× native lysis buffer (NLB) with protease inhibitors and briefly sonicated in a Bioruptor water bath sonicator (30 s on, 30 s off, five cycles at 4 °C). Lysates were then centrifuged at 20,000 relative centrifugal force (rcf) for 10 min at 4 °C to remove insoluble material. Supernatant was transferred to a fresh tube with 25 µl of MyONE C1 streptavidin beads (Thermo) and incubated in a cold room with end-to-end rotation for 1 h. Beads were washed once with high-salt buffer (HSB), once with non-denaturing buffer (NDB), treated with 0.02 U µl−1 RNase I (Thermo) in 100 µl of NDB for 3 min at 37 °C and immediately placed on ice to stop the reaction. Beads were then washed once each with HSB and NDB. RNA ends were repaired with T4 polynucleotide kinase, after which barcoded s-oligos were ligated with T4 RNA ligase 1 for 90 min at 25 °C. The 3′ phosphate at the 3′ end of each s-oligo was removed with recombinant shrimp alkaline phosphatase (NEB, M0371) and beads were washed once each with lithium dodecyl sulfate buffer, protein lysis buffer and HSB, and finally with NDB. RNA was released by treatment with proteinase K and purified using Oligo Clean and Concentrator columns (Zymo). Reverse transcription was carried out with SuperScript III and samples then treated with RNase H (NEB) to phosphorylate the 5′-end of the cDNA molecule. Following a final round of purification with Oligo Clean and Concentrator columns (Zymo), cDNA was circularized with CircLigaseII (Lucigen) and amplified with Q5 polymerase (NEB). PCR products were purified with solid-phase reversible immobilization beads, quality controlled with Bioanalyzer and subjected to high-throughput sequencing.

    FLASH data processing

    Paired-end reads were merged with bbmerge.sh v. 38.72 using the following command: bbmerge.sh in1 = {R1.fastq.gz} in2 = {R2.fastq.gz} out = {merged.fastq.gz} outu1 = {unmerged.R1.fastq.gz} outu2 = {unmerged.R2.fastq.gz} ihist = {histogram.txt} adapter1=AGATCGGAAGAGCACACGTCTGAACTCCAGTCACCCAACAATCTC adapter2=AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG –mininsert=1. Short inserts (below 20 nt, following removal of the unique molecular identifier (UMI) and internal index) were removed with bbduk.sh v. 38.72 bbduk.sh in = {infile} out = {out} minlen=34. The UMI was removed from reads and written to the header with UMI_tools v.1.0.0: umi_tools extract –bc-pattern=NNNXXXXXXNNNNN -I {IN.fastq.gz} -−3prime –stdout = {OUT.fastq.gz}, followed by separation of replicates with flexbar v.3.5.0: flexbar -r INPUT.fastq.gz -b barcodes.fa –barcode-trim-end RTAIL –barcode-error-rate 0.2 –zip-output GZ. Reads were aligned first to abundant RNAs such as transfer RNA, small nuclear RNA, small nucleolar RNA and ribonuclear RNA, then to the genome with bowtie2 v.2.3.5: bowtie2 –no-unal –un-gz -L 16 –very-sensitive-local -x bt2_index -U fastq_in.fastq.gz -o bam_out.bam. Unaligned reads were remapped to the genome with bbmap.sh v.38.72 to capture spliced reads: bbmap.sh -Xmx50G in = {fastq_in} out = {bam_out} outu = {unmapped_out} ref = {reference.fa} sam=1.3 mappedonly=t mdtag=t trimreaddescriptions=t nodisk. Finally, PCR duplicates were removed using UMI-tools: umi_tools dedup -I in_bam -S out_bam –spliced-is-unique –soft-clip-threshold 3 –output-stats = {stats}. Coverage files were generated with bamCoverage v.3.3.1: bamCoverage -b bam –filterRNAstrand [forward | reverse] –binSize 1 –normalizeUsing CPM –exactScaling -o out_file.

    UMAP of FLASH data

    For construction of the UMAP, peak calling was carried out on all profiles using HOMER: findPeaks {tag_directory} -style factor -strand separate -o {peaks.txt} -i {background_tag_directory}. Peaks from all profiles were then merged with: mergePeaks -strand -d given -matrix {peaks1.txt peaks2.txt …} > merged.peaks.txt. A count matrix, using all alignments from all profiles against merged peaks, was then created with featureCounts v.2.0.1: featureCounts -F SAF -Q 10 –primary -s 1 -T 12 -a {merged_peaks} -o {merged_peaks.counts.txt} {all_bam_files}. The count matrix was imported into a Jupyter notebook with pandas: peaks = pd.read_csv(“merged_peaks.counts.txt”, sep = ”\t”, index_col = ”Geneid”), scaled with sklearn.preprocessing.StardardScaler: peaks_scaled = StandardScaler().fit_transform(peaks), which was then used to create the UMAP: peaks_scaled_mapper = umap.UMAP(n_neighbors=15, random_state=42).fit(peaks_scaled), and plotted using umap.plot.points function. Clusters were called with HDBSCAN: clusterable_embedding = umap.UMAP(n_neighbors=30, min_dist=0.0, n_components=14, random_state=42).fit_transform(peaks_scaled), then hdbscan_labels = hdbscan.HDBSCAN(min_samples=100, min_cluster_size=600, core_dist_n_jobs=1).fit_predict(clusterable_embedding).

    Sample and library preparation for RNA-seq

    Flp-In T-REx HEK293 and HeLa ACC57 cells were transfected at a final concentration of 5 nM each (in the case of triple knockdown, total siRNA concentration became 15 nM and hence single-knockdown transfections were increased to 15 nM with the addition of 10 nM negative control siRNA) using Silencer Select siRNAs (Thermo Fisher Scientific, catalogue no. 4427037 for 1 nM scale) and RNAiMAX (Thermo Fisher Scientific, catalogue no. 13778030) on six-well plates (around 200,000 were used per replicate). Silencer Select siRNAs are 21 nt long, chemically modified (the exact modification is proprietary; Thermo Fisher) and reduce overall off-target effects by up to 90% without compromising potency. This modification also exaggerates strand bias, which correlates with better knockdown, and therefore they are 5- to 100-fold more potent than other siRNAs. The siRNA ID for human SAFB1 is s12452, for SAFB2 is s18599 and for SLTM is s36384. Cells were harvested on the second day of knockdown.

    The Silencer Select siRNAs used were s29362 for MPP8 was s23449 for TASOR.

    Flp-In 3T3 cells were first reverse transfected (roughly 100,000 per replicate) with 5 nM siRNA, boosted with the same amount 24 h following knockdown (forward transfected) and harvested on the third day following initial transfection. The siRNA ID for mouse Safb1 is s104978, for Safb2 is s104977 and, because the human SLTM siRNA also targets mouse mRNA, the same siRNA was used.

    Drosophila S2R+ cells (DGRC no. 150) were transfected with control dsRNA against GFP or Saf-B using FuGENE HD (Promega) for 3 days, after which cells were harvested for RNA isolation.

    Total RNA from human, mouse or Drosophila cells was extracted with the Quick-RNA MicroPrep kit (Zymo). Polyadenylated RNA was isolated from total RNA with the Dynabeads mRNA Purification Kit (Thermo). Purification was carried out twice to enrich poly(A)+ RNA. Sequencing libraries were generated using the KAPA Stranded RNA-Seq Library Preparation Kit (Roche).

    Isolation of nuclear and cytoplasmic RNA for RNA-seq

    Forty-eight hours following siRNA transfection (control or SAFB1 + SAFB2 + SLTM, 5 nM each), approximately 1 million Flp-ln T-REx HEK293 cells per replicate were trypsinized and either used directly for RNA isolation (total sample) or resuspended with a buffer containing 0.5% Igepal CA-630 to separate nuclear and cytoplasmic fractions, as described in ref. 57. Nuclear and cytoplasmic RNAs were isolated with the Quick-RNA MicroPrep kit (Zymo). Ribo-depleted RNA-seq samples were prepared using the KAPA RNA HyperPrep Kit with RiboErase (HMR) (no. KK8560, Roche).

    Transient transfections in rescue experiments and sample preparation for qPCR detection

    SAFB triple knockdown was performed on Flp-In T-REx HEK293 cells as described above, and then FuGENE HD forward transfected with WT or truncation mutants as shown in Extended Data Fig. 7f while at the same time refreshing the medium 6 h following transfection of siRNAs. Transgenes were induced on day 1 of knockdown with 0.1 µg ml−1 DOX for 24 h. On day 2 of knockdown, total RNA extracts were prepared with the Zymo Quick-RNA Kit and first-strand cDNA synthesis was carried out with PrimerScript RT Master Mix (TaKaRa, no. RR036A). Quantitative real-time PCR was performed using the oligos listed in Supplementary Table 1 with the Blue S’Green qPCR Kit (Biozym, no. 331416).

    ONT direct RNA-seq

    Isolation of polyA-enriched mRNA from Flp-ln T-REx HEK293 cells treated with either control siRNA or siRNAs against SAFB1, SAFB2 and SLTM (5 nM each) for 2 days was carried out using the Dynabeads mRNA DIRECT purification kit (Thermo Fisher Scientific) following the manufacturer’s instructions, with minor modifications. In brief, approximately 4 × 106 cells were subjected to the standard protocol and hybridization of the beads/mRNA complex was carried out for 10 min on a Mini Rotator (Grant-bio). DNA containing supernatant was removed and the beads were resuspended with 2 × 2 ml of buffer A following a second wash step with 2 × 1 ml of buffer B. Purified RNA was eluted with 10 µl of preheated elution buffer (10 mM Tris-HCl pH 7.5) for 5 min at 80 °C. Quantification of isolated mRNA was performed using a Qubit Fluorometer together with the RNA HS Assay kit (Thermo Fisher Scientific). For direct RNA-seq, 700 ng of freshly isolated polyA-enriched mRNA was processed according to the manufacturer’s protocol (no. SQK-RNA002). Final sequencing libraries were then loaded on R9.4 flow cells and sequenced on MinION and PromethION sequencers.

    Retrotransposition assay

    The transfection and experimental timeline for the retrotransposition assay was followed as described in ref. 18. Initially around 200,000 HeLa cells were transfected, with the same siRNAs and under the conditions listed above, on a six-well plate with 5 nM final concentration each of negative control, SAFB1, SAFB2 and SLTM siRNAs. The following day, knockdown HeLa cells were transfected with 200 ng of plasmids pYX015 (based on JM111, which has a point mutation in ORF1p) for background control and pYX017 (pCAG-driven L1RP) for L1 activity in triplicates, using Lipofectamine 2000 on a 48-well plate in triplicate. Twenty-four hours following reporter construct transfection, 2.5 µg ml−1 puromycin selection was started and maintained for 3 days (that is, day 5 of knockdown). Cells were washed with PBS before lysing with 40 µl of passive lysis buffer from the Dual-Luciferase Reporter Assay System (Promega, catalogue no. E1960). Half of the lysate was transferred to a 96-well, reading-compatible plate and measured using an Omega Lumistar machine.

    RNA–FISH

    FISH was carried out in HCT116 cells transfected with control versus siRNAs against SAFB1 and SLTM (no SAFB2 expression was detected in HCT116 cells) for 48 h using the Stellaris RNA–FISH kit (https://www.biosearchtech.com/assets/bti_stellaris_protocol_adherent_cell.pdf). Probes against L1Hs were synthesized by LGC Biosearch Technologies (see Supplementary Table 2 for sequences). Probes against GAPDH were sourced from LGC Biosearch Technologies (SMF-2026-1), provided by M. Bothe. Probes were used at a concentration of 125 nM and hybridized for 16 h at 37 °C. Samples were imaged using a Leica Stellaris 8 confocal microscope.

    EMSA with recombinant Halo, Halo-SAFB1RRM and Halo-TRA2BRRM

    The RNA-binding domain of TRA2B (residues 111:201) and SAFB1 (residues 386:485) were cloned into a plasmid encoding 10× His-TEV-Halo. Three constructs (Halo only, Halo-TRA2BRRM and Halo-SAFB1RRM) were then expressed using BL21-CodonPlus(DE3)-RIL bacteria, which were induced when an optical density of roughly 0.6 was reached, with 0.2 mM isopropyl-ß-d-thiogalactopyranoside for 4 h at 37 °C, then collected by centrifugation. Bacteria were resuspended with lysis buffer (50 mM HEPES pH 8.0, 300 mM NaCl, 5 mM imidazole and 0.05% Igepal CA-630) and disrupted with a Branson sonifier, clarified by centrifugation and filtered through a 0.45 µm membrane. Cleared lysates were incubated with cOmplete His-Tag Purification Resin (Roche), washed extensively with lysis buffer and incubated with 0.5 µM OregonGreen (Promega) on beads in lysis buffer at room temperature for 30 min for fluorescent labelling of proteins. Beads were first washed extensively with lysis buffer, then with high-salt wash buffer (50 mM Tris.Cl pH 8.0, 1 M NaCl, 5 mM imidazole) and lastly with lysis buffer. Proteins were eluted with elution buffer (50 mM Tris.Cl pH 8.0, 100 mM KCl, 200 mM imidazole). Eluates were pooled, dithiothreitol (DTT, 1 mM final concentration) and TEV protease (home-made, 6× His-tagged, approximately 1:100) were added and samples dialysed against 25 mM Tris.Cl pH 7.4, 50 mM KCl, 5% glycerol and 1 mM DTT overnight in a cold room (about 8 °C). Dialysed eluates were then incubated with cOmplete His-Tag Purification Resin (Roche) for removal of TEV protease and undigested proteins, and flowthrough was centrifuged at 23,000 rcf for 30 min and filtered through a 0.22 µm membrane to remove particulate matter. The UV spectra showed no significant absorption at 260 nm and were used to quantify purified proteins, which were then normalized and their quality checked with PAGE and Coomassie staining (Fig. 4a). Concentrations used in EMSAs were: Halo-TRA2BRRM (lanes 2–6: 3.6, 7.2, 14.4, 57.6 and 102.4 µM, respectively); Halo-SAFBRRM (lanes 7–11: 3.6, 7.2, 14.4, 57.6 and 102.4 µM, respectively); and Halo (lane 12: 102.4 µM). Lane 1 contained only those probes with no added protein.

    The RNA probes were prepared by in vitro transcription. Briefly, a plasmid containing the relevant sequence TAATACGACTCACTATAGGGAAGAAGAAGAAGAAGAAGAAGAT^ATC, in which the T7 promoter sequence is underlined, was digested with EcoRV (site of digestion, indicating that the last nucleotide of the final RNA is marked—indicated by ^), purified and in vitro transcribed using a HighYield T7 RNA Synthesis Kit (Jena Biosciences, no. RNT-101) with either 1 mM (final) CTP/UTP/GTP/ATP or 1 mM CTP/UTP/GTP and 1 mM N6-Methyl-ATP (Jena Biosciences, no. RNT-112-S), completely replacing ATP. RNA was cleaned up using SPRI beads to remove the plasmid and other potential high-molecular-weight products, then with the OCC-5 kit (Zymo). RNA was then oxidized using freshly prepared sodium periodate (250 mM in water, final concentration 10 mM; Sigma, no. 311448) in 60 mM NaOAc pH 5.5 for 1 h on ice, with tubes kept in the dark. After a further clean-up with OCC-5, RNA was then labelled with CF 647 Hydrazide (Sigma, no. SCJ4600046; 10 mM in water, 0.8 mM final concentration in approximately 120 mM NaOAc, pH 5.5) at room temperature overnight. RNA was purified with OCC-5, eluted in water and normalized to 5 µM. EMSAs were carried out in 25 mM Tris.Cl pH 7.4, 50 mM KCl, 5% glycerol and 1 mM DTT with an RNA probe of around 100 nM and the indicated concentration of the protein of interest. Following incubation of RNA and proteins on ice for 30 min, mixtures were loaded directly on a Nature 8% polyacrylamide gel cast with 0.5× Tris-borate-EDTA (final) and run in 0.5× Tris-borate-EDTA in a cold room for 45 min at 100 V (gels were prerun at 100 V for 15 min). Proteins and RNA were sequentially visualized on the same gel using a Typhoon Scanner with appropriate excitation lasers and emission filters.

    In vitro unmethylated and methylated RNA-binding assay

    Nuclei were isolated from wt-HCT116 cells using a buffer containing 0.5% Igepal CA-630, following Lubelsky and Ulitsky57, and snap-frozen in liquid nitrogen until use. Nuclei were resuspended with 500 µl of 25 mM Tris.Cl pH 7.4, 150 mM KCl, 2 mM MgCl2, 0.5% Igepal CA-630, 5% glycerol, 5 mM β-mercaptoethanol, 1× protease inhibitors and 1× PhosSTOP and sonicated with a Branson sonifier. Next, 15 µl of TURBO-DNase was added followed by incubation at 25 °C for 20 min and then by the slow addition to the lysate of 1.5 m of base buffer (25 mM Tris.Cl pH 7.4, 50 mM KCl, 5% glycerol) to bring the KCl concentration to 75 mM and Igepal CA-630 concentration to 0.125% (final). Lysate was incubated with 50 µl of Pierce Control Agarose Resin (no. 26150) for 20 min, with rotation in a cold room, and spun down at full speed for 10 min at 4 °C to remove insoluble material. A 949 bp fragment of L1 ORF2 was amplified from pYX017 using primers AATAATACGACTCACTATAGCGTATCACCACCGATCCCACAG (T7 promoter underlined) and GGCTGAGACGATGGGGTTTT and in vitro transcribed using a HighYield T7 RNA Synthesis Kit (Jena Biosciences, no. RNT-101) with either 1 mM (final) CTP/UTP/GTP/ATP or 1 mM CTP/UTP/GTP and 1 mM N6-methyl-ATP (Jena Biosciences, no. RNT-112-S), completely replacing ATP. RQ1 DNase (Promega) was added to each reaction with incubation for for 20 min at 37 °C, after which RNA was cleaned up using RCC-25 (Zymo) and oxidized with freshly prepared sodium periodate (250 mM in water, final concentration 10 mM; Sigma, no. 311448) in 60 mM NaOAc pH 5.5 for 1 h on ice, with tubes kept in the dark. After a further clean-up with RCC-25, RNA was then labelled with biotin Hydrazide (Sigma, no. 87639; 50 mM in DMSO, 2 mM final concentration in approximately 120 mM NaOAc, pH 5.5) at room temperature overnight. RNA was purified with RCC-25, eluted in water and quantified with Nanodrop, then 5 µg of each RNA or buffer was incubated with 25 µl of MyONE C1 streptavidin beads in base buffer + 0.1% Igepal CA-630 for 1 h at room temperature and washed twice with base buffer + 0.1% Igepal CA-630. The nuclear lysate was incubated with these beads for 1 h at 16 °C, with shaking at 1,100 rpm. Beads were washed and transferred from fresh tubes with base buffer + 0.1% Igepal CA-630. Proteins bound to the beads were eluted with base buffer + 0.1% Igepal CA-630 + 2 µl of RNaseA + T1 (no. EN0551, Thermo Fisher Scientific) for 30 min at 30 °C and demonstrated by immunoblotting.

    RNA blotting

    HCT116 cells were transfected with 5 nM siRNA (as indicated in Fig. 2h) then, 48 h later, were either transfected with a plasmid encoding L1Hs and driven by a minimal EF1alpha (without an intron) promoter or mock transfected. Twenty-four hours later (72 h post siRNA transfection), cells were trypsinized and resuspended with a buffer containing 0.5% Igepal CA-630, essentially as described in ref. 57. The cytoplasmic fraction was purified with RNA Clean & Concentrator columns (Zymo), 2 µg of which was loaded onto 1.2% agarose gel and electroblotted to a nylon membrane. DIG-labelled probes against ORF2 were prepared with in vitro transcription (see Supplementary Table 2 for primers) and probe hybridization, washes and imumunodetection were carried out as described in the manual of the DIG Northern Starter Kit (Roche, no. 12 039 672 910).

    p-SR (1H4) and DHX9 FLASH in SAFB-depleted cells

    Flp-In T-REx HEK293 cells were transfected with either control siRNA or siRNAs against SAFB1, SAFB2 and SLTM 48 h following transfection, then washed with PBS and UV-crosslinked with 0.2 mJ cm2 UV-C light on ice. Nuclei were isolated as described in ref. 57, resuspended in 1× NLB + 5 mM MgCl2 with protease and phosphatase inhibitors and sonicated using a Branson sonifier. Following centrifugation, to remove insoluble material the supernatant was incubated with an agarose resin (Pierce, no. 26150) for 20 min in a cold room followed by further incubation with Dynabeads Protein G beads prebound to p-SR antibody (10 µl per IP; 1H4, Santa Cruz, no. sc-13509) for 90 min in a cold room. The supernatant from 1H4 IP was used for DHX9 IP (2.5 µl per IP; abcam, no. ab26271). The FLASH protocol was identical to that described above, except that all HSB washes were replaced with NLB and s-oligos were pre-dephosphorylated to skip the recombinant shrimp alkaline phosphatase treatment that could dephosphorylate SR proteins on the beads, potentially leading to their elution.

    RIP–qPCR

    Flp-In T-REx HEK293 cells were crosslinked with 0.2% formaldeyhde for 10 min at room temperature, extensively washed with PBS, resuspended with 1× NLB and sonicated using a Branson sonifier. The lysate was centrifuged at 23,000 rcf for 10 min at 4 °C to remove insoluble material and the supernatant then incubated with an agarose resin (Pierce, no. 26150) for 30 min in a cold room. Following brief centrifugation, the supernatant was used for IP with Dynabeads Protein G beads coupled to either an antibody against SAFB1 (10 µl per IP; Santa Cruz, no. sc-393403) or control IgG (Santa Cruz, no. sc-2025) overnight in a cold room. Beads were washed with 1× NLB and bead-bound RNA was eluted with proteinase K, as described above, purified using RCC-5 (Zymo) and utilized for RT–qPCR.

    Generation of the Dnmt3c-null allele

    Dnmt3C knockout animals were generated as described in ref. 58. For specific abolition of enzymatic activity we designed a sgRNA against the methyltransferase domain of Dnmt3C targeted to exon 15 with the following protospacer sequence: 5′-GGACATCTCACGATTCCTGG-3′. P0 animals were genotyped using Sanger sequencing following PCR with primers 5′-CTGGCCGGCTCTTCTTTGAG-3′ and 5′-GGAAATCATTCCCACCTGTCAGC-3′. The founding animal was chosen based on a 31 bp deletion, which resulted not only in a frameshift mutation beginning at codon 598 but simultaneous removal of a PfoI restriction enzyme digestion site for straightforward genotyping. The founder mutation was subsequently backcrossed into the C57BL/6 J background. Homozygous knockout males were validated as infertile, with significantly smaller and disordered testes by P42, as reported previously51. The generation of these experimental animals was regulated following ethical review by Yale University Institutional Animal Care and Use Committee (protocol no. 2020-20357) and was performed according to governmental and public health service requirements. No sample size selection, randomization or blinding was performed.

    Direct antibody labelling

    The Mix-n-Stain CF488 A Antibody Labelling Kit (Biotium, no. 92253) and Mix-n-Stain CF555 Antibody Labelling Kit (Biotium, no. 92254) were used to label rabbit antihuman SAFB1/SAFB antibody (LSBio, LS-C286411) and rabbit anti-LINE-1-ORF1p antibody (abcam, no. ab216324), respectively. The standard protocol listed on the product website was followed, including the ultrafiltration protocol, with minor modifications. In brief, 25–35 μg of antibody was placed in the ultrafiltration vial provided and centrifuged at 14,000g for 2 min to remove all liquid. Depending on the initial amount of antibody, antibodies were eluted in 1× PBS to a final concentration of 0.75 ng μl−1 and the appropriate volume of 10X Mix-n-Stain Reaction Buffer added. The entire solution was transferred to the vial containing the dye and the labelling reaction allowed to proceed at room temperature (22–23 °C) in the dark for 30 min. Finally, 150 μl of storage buffer was added to each reaction with storage in aliquots of 50 μl at −20 °C until use.

    Testis sectioning and Immunofluorescence microscopy

    Testes from P25 Dnmt3C homozygous and heterozygous mutant males were dissected and embedded in O.C.T. compound (Tissue-Tek). Using cryosectioning, 8 μm sections were obtained with a Leica CM3050S and spotted onto Fisherbrand Superfrost Plus Microscope Slides (Fisher Scientific, no. 12-550-15) and stored at −80 °C until use. For immunofluorescence detection, slides were thawed at room temperature for over 10 min before fixing in 4% paraformaldehyde for 8 min. Permeabilization and blocking were performed at room temperature for 1 h with blocking buffer (5% bovine serum albumin (BSA), 0.2% Triton X-100 and PBS). Sections were incubated with directly labelled antibodies overnight at 4 °C, followed by three 5 min washes in 1× PBS and mounting with VECTASHIELD PLUS Antifade Mounting Medium and DAPI (Vector Laboratories, no. H-2000). Images were acquired using a Leica THUNDER Imaging System at ×40 magnification.

    Mass spectrometry

    Flp-In T-REx HEK293 cells stably expressing SAFB1, SAFB2 or SLTM (same cell lines used for FLASH) were induced with 0.1 µg ml−1 DOX for 16 h in triplicate, lightly crosslinked with formaldehyde (0.016% final) at room temperature for 10 min, extensively washed with PBS, resuspended with HMGT-K200 buffer (25 mM HEPES-KOH pH 7.4, 10 mM MgCl2, 10% glycerol, 0.2% Tween-20) and homogenized using a water bath sonicator. Following centrifugation, supernatants were then incubated with MyONE C1 streptavidin beads to pull down proteins of interest. Beads were washed with HMGT-K200, 20 mM Tris-Cl pH 7.4 and 1 M NaCl and finally with 20 mM Tris-Cl pH 7.4 and 50 mM NaCl, then submitted to the in-house MS-facility for further processing. Silver gel staining was performed using a SilverQuest Silver Staining Kit (Thermo Fisher Scientific, no. LC6070) for SAFB1 to ensure that conditions were sufficiently stringent in comparison with GFP pulldown (Extended Data Fig. 7b).

    On-beads digest and mass spectrometry analysis

    Twelve samples were boiled at 95 °C and 500 rpm for 10 min, followed by tryptic digest including reduction and alkylation of cysteines. The reduction was performed by the addition of tris(2-carboxyethyl)phosphine at a final concentration of 5.5 mM at 37 °C on a rocking platform (500 rpm) for 30 min. To perform alkylation, chloroacetamide was added at a final concentration of 24 mM at room temperature on a rocking platform (500 rpm) for 30 min. Proteins were then digested with 200 ng of trypsin (Roche) per sample, shaking at 800 rpm and 37 °C for 18 h. Samples were acidified by the addition of 1.3 µl of 100% formic acid (2% final concentration), centrifuged and placed on a magnetic rack. Supernatants containing the digested peptides were transferred to a new low-protein-binding tube. Peptide desalting was performed on self-packed C18 columns in a Tip. Eluates were lyophilized and reconstituted in 19 µl of 5% acetonitrile and 2% formic acid in water, briefly vortexed and sonicated in a water bath for 30 s before injection into nano-liquid chromatography–tandem mass spectrometry (nano-LC–MS/MS).

    LC–MS/MS instrument settings for shotgun proteome profiling and data analysis

    LC–MS/MS was carried out by nanoflow reverse-phase liquid chromatography (Dionex Ultimate 3000, Thermo Scientific) coupled online to a Q-Exactive HF Orbitrap mass spectrometer (Thermo Scientific), as reported previously59. In brief, LC separation was performed using a PicoFrit analytical column (75 μm internal diameter × 50 cm length, 15 µm Tip ID; New Objectives) and packed in house with 3 µm of C18 resin (Reprosil-AQ Pur, Dr Maisch). Peptides were eluted using a gradient from 3.8 to 38% solvent B in solvent A over 120 min at a flow rate of 266 nl min−1. Solvent A was 0.1% formic acid and solvent B comprised 79.9% acetonitrile, 20% H2O and 0.1% formic acid. Nanoelectrospray was generated by the application of 3.5 kV. A cycle of one full Fourier transformation scan mass spectrum (300–1,750 m/z, resolution 60,000 at m/z 200, automatic gain control target 1 × 106) was followed by 12 data-dependent MS/MS scans (resolution of 30,000, automatic gain control target 5 × 105) with a normalized collision energy of 25 eV. To avoid repeated sequencing of the same peptides, a dynamic exclusion window of 30 s was used.

    Raw MS data were processed with MaxQuant software (v.1.6.17.0) and searched against the human proteome database UniProtKB UP000005640 (containing 75,074 protein entries, released May 2020). The parameters of MaxQuant database searching were a false discovery rate of 0.01 for proteins and peptides, a minimum peptide length of seven amino acids, a first-search mass tolerance for peptides of 20 ppm and a main search tolerance of 4.5 ppm. A maximum of two missed cleavages was allowed for the tryptic digest. Cysteine carbamidomethylation was set as a fixed modification whereas N-terminal acetylation and methionine oxidation were set as variable modifications. The MaxQuant-processed output files can be found in Supplementary Table 3, showing peptide and protein identification, accession numbers, percentage sequence coverage of the protein and q-values.

    IP

    Native whole-cell extracts prepared using 0.5× NLB were incubated with ProtG Dynabeads (Life Technologies, no. 10004D) coupled to 1 μg of either SAFB antibody (‘Antibodies’) or IgG (mouse; Santa Cruz, no. sc-2025) in a cold room for 150 min. Beads were washed twice in 0.5× NLB for 5 min then once with NDB. RNase-treated samples were resuspended in 90 µl of NDB to which 10 µl of RNaseA + T1 mix (Thermo Scientific, no EN0551) was added. Samples were then incubated at 20 °C for 15 min and washed twice with 0.5× NLB. Elution from the beads was performed in 1× protein-loading dye by incubation for 5 min at 95 °C with shaking. Interaction partners were detected using the antibodies against proteins shown in Extended Data Fig. 7 (‘Antibodies’).

    Immunofluorescence

    Cells were crosslinked with 4% methanol-free formaldehyde in PBS at room temperature for 10 min, permeabilized with 0.5% Triton X for 10 min then blocked with 5% BSA in PBS for 30 min at room temperature. Primary antibodies (further details in ‘Antibodies’) were diluted in PBS with 0.1% Triton X and 1% BSA and incubated with fixed cells at 4 °C for about 16 h. Fluorescently labelled secondary antibodies with the appropriate serotype were used to demonstrate target proteins. Hoechst 33342 was used to stain DNA.

    Antibodies

    The following antibodies were used: AFB1 (Santa Cruz, no. sc-393403), SAFB2 (Santa Cruz, no. sc-514963), SAFB1/2 (HET) (human: Merck/Sigma-Aldrich, no. sc05-588; mouse: LSBio, no. LS-C2886411), SLTM (Invitrogen, no. PA5-59154), ORF1p (human: abcam, no. ab230966; mouse: abcam, no. ab216324), TASOR (Sigma-Aldrich, no. HPA006735), 1H4 (p-SR) (Merck/Sigma-Aldrich, no. MABE50), RBM12B (Bethyl, no. A305-871A-T), RBMX (Cell Signaling Technology, no. 14794 S), NCOA5 (Bethyl, no. A300-790A-T), ZNF638 (Sigma-Aldrich, no. ZRB1186), ZNF326 (Santa Cruz, no. sc-390606), TRA2B (Bethyl, no. A305-011A-M), U2AF2 (U2AF65; Santa Cruz, no. sc-53942), TUBULIN (Santa Cruz, no. sc-32293), SRRM1 (abcam, no. ab221061), SRRM2 (SC35) (Sigma-Aldrich, no. S4045), SON (Sigma-Aldrich, no. HPA023535), DHX9 (abcam, no. ab183731), U1-70K (SySy, no. 203011), PRP8 (Santa Cruz, no. sc-55533), RNAPII (Creative Biolabs, no. CBMAB-XB0938-YC), IgG normal mouse (Santa Cruz, no. sc-2025), SRSF1 (Santa Cruz, no. sc-33652), SRSF2 (abcam, no. ab204916), SRSF3 (Elabscience, no. E-AB-32966), SRSF7 (MBL, no. RN079PW), RB1 (Cell Signaling Technology, no. 9309 S), TRA2B (Santa Cruz, no. sc-166829) and YTHDC1 (Proteintech, no. 14392-1-AP).

    TE expression analysis

    RNA-seq data from human (HEK293, HeLa, HCT116), mouse (3T3) and Drosophila (S2) cells were mapped to their respective genome (hg38, mm10 and dm6, respectively) using the snakePipes non-coding-RNA-seq pipeline60. Internally this pipeline uses TEtranscripts23, which estimates both gene and TE transcript abundance in RNA-seq data and conducts differential expression analysis on the resultant count tables, which is carried out by DESeq2 (ref. 61). The outputs of this analysis can be found in Supplementary Tables 4–11.

    SAFB peak annotation and TE enrichment

    Overlapping SAFB1, SAFB2 and SLTM regions called by HOMER on FLASH data were merged using the function IRanges::reduce(), resulting in a single set of 29,806 SAFB-bound genomic intervals (SAFB peaks), 23,136 of which were located inside GENCODE-annotated genes (within-gene SAFB peaks). All GENCODE v.29 genes located on standard chromosomes were used as a control set (n = 58,721). repeatMasker annotation was downloaded from the UCSC genome browser, and the fraction of total length contributed by different transposable elements was calculated for 23,136 SAFB peaks and 58,721 GENCODE-annotated genes, separately for TEs inserted in sense and antisense orientation. Enrichment was calculated for a subset of sense and antisense TEs by dividing the TE fraction in peaks (that is, observed TE fraction) by that in whole genes (that is, fraction expected if SAFB peaks were distributed randomly on transcripts), followed by log2-transformation of values.

    Short-read RNA-seq data analysis

    Raw RNA-seq reads were subject to adaptor and quality trimming using cutadapt 4.1. Default options were used, except for -q 16 –trim-n -m 25 -a AGATCGGAAGAGC -A AGATCGGAAGAGC.

    Trimmed reads from human and mouse cell lines were mapped to human GRCh38 (HEK293, HeLa and HCT116 cell lines) and mouse GRCm38 (3T3 cell line) genomes using the STAR 2.7.9a aligner62. To improve the sensitivity of spliced read detection and quantification, mapping was done in two passes. In the first pass, all reads were mapped simultaneously to the STAR genome index built with GENCODE gene models (v.29 for human, v.19 for mouse) using default options, with the exception of –outFilterMismatchNoverReadLmax 0.05 –outSAMtype None. In the second pass, each sequenced library was mapped to a genome index with GENCODE gene models extended with new splice junctions detected in the first pass (–sjdbFileChrStartEnd pass1.SJ.out.tab). Other non-default STAR options used included –outFilterMismatchNoverReadLmax 0.05 –quantMode GeneCounts –alignIntronMax 1000000 –alignMatesGapMax 2000000 –sjdbOverhang 100 –limitSjdbInsertNsj 2000000.

    Trimmed reads from the fruitfly S2 cell line were mapped to the dm6 genome assembly using STAR 2.7.4a, and reads were counted using featureCounts (subread package v.2.0.0).

    Differential gene expression

    Differential gene expression analysis was performed using the DESeq2 package61 on reverse-stranded gene counts from the STAR alignment step. Genes with fewer than ten mapped reads were discarded; lfcThreshold = 1 and alpha = 0.05 were used for calling of differentially expressed genes, and results were shrunk using lfcShrink(…, type = “ashr”).

    Differential exon usage

    To avoid assignment of exonic reads to SAFB peaks, within-gene SAFB peak fragments or entire peaks overlapping GENCODE v.29-annotated exons were masked and ignored in exon usage analysis. The 22,129 peaks remaining (intronic SAFB peaks) were assigned to their host genes and RNA-seq reads were counted on both annotated exons and intronic SAFB peaks using the function Rsubread::featureCounts() with default arguments, except for countMultiMappingReads = FALSE, strandSpecific = 2, juncCounts = TRUE, and isPairedEnd = TRUE. Differentially expressed SAFB peaks were identified using the DEXSeq R package63 and, for each gene, the peak with the lowest DEXSeq P value was used as a reference for gene fragmentation. In total, 5,394 affected genes were fragmented into pre- and post-peak parts. Exonic read counts were aggregated separately for pre- and post-peak fragments and their differential expression measured using DESeq. Genes hosting SAFB peaks with DEXSeq Padjusted < 0.05 and log-fold change above 2 were classified as (genes with) upregulated peaks (n = 878) whereas those hosting peaks with DEXSeq Padjusted > 0.05 and log-fold change between −0.5 and 0.5 were used as the control set (n = 1,457).

    Differential splice junction usage

    The number of RNA-seq reads supporting each splice junction was counted in the second STAR alignment pass (SJ.out.tab file). Splice junctions that could not be unambiguously assigned a host gene, or that were supported by fewer than ten reads in total across all treatments and replicates in a given cell line, were ignored. Differentially used splice junctions were identified using DEXSeq, with default settings; splice junctions were treated as feature IDs and host genes as group IDs.

    Splice site strength quantification

    For each gene in the human genome, the probability of each nucleotide acting as a splice donor or acceptor was estimated using SpliceAI26, with default options. SpliceAI scores were matched to splice junctions detected and quantified by STAR.

    Splice site to TE distance measurement

    Distances between splice sites and nearest upstream or downstream TEs were calculated for a set of ten repeat families (L1, L2, Alu, SVA, ERVL, ERV1, TcMar-Tigger, MIR, Simple_repeat, hAT_Charlie) as follows: (1) all GENCODE genes were flattened using the function IRanges::reduce() in R; (2) STAR-detected splice junctions and repetitive elements outside annotated genes were dropped; and (3) for each remaining splice donor and acceptor, the distance (in nucleotides) to the nearest sense or antisense TE within the same flattened gene was measured separately for each of the ten repeat families. Donors and acceptors within TEs were assigned the distance of 0 nt.

    New splice acceptors within SAFB peaks in human tissues

    The number of reads supporting splice junctions in the GTEx consortium tissue data was extracted using the recount3 R package64. Tissues with fewer than 1 billion spliced reads were excluded from further analysis. Alternative splicing was quantified in an intron-centric manner—that is, splicing index was calculated separately for each splice donor and acceptor. We extracted all splice junctions located within an annotated human gene, with splice donor annotated in GENCODE v.29 and splice acceptor sited within a fully intronic SAFB peak (npeaks = 16,929). A further 21,693 such splice junctions were filtered for junction where the donor participated in multiple events, had a splicing index above 1% in at least one tissue and was supported by at least 500 reads in all 27 tissues (that is, used ubiquitously), resulting in a highly stringent set of of 1,104 splice junctions.

    p-SR and DHX9 FLASH analysis

    FLASH reads uniquely mapping to the hg38 genome were counted using featureCounts on two custom gene annotation reference sets. The first of these contained exons and SAFB peaks, with exons prioritized over SAFB peaks in the case of overlaps. SAFB peaks were assigned to their host genes and treated as exons for read counting. The second reference contained genes fully fragmented into exons, repetitive elements and introns, with exons prioritized over repeats and introns, and repeats prioritized over introns where their genomic coordinates were overlapping. Whereas the first reference allows for increased sensitivity when quantifying FLASH signal on known SAFB-binding regions, the latter sacrifices sensitivity (because it contains many short genomic fragments) for the power of recognizing regions of increased binding outside of SAFB peaks, or in SAFB peaks not called by the peak-calling software. DEXSeq analysis was performed separately on exon/peak and exon/repeat/intron counts. Regions with adjusted P < 0.05 were considered differentially bound.

    Alternative polyadenylation sites

    Aligned ONT direct RNA-seq performed on control and triple KD samples was screened for their end coordinates, under the assumption that these are derived from the close proximity of a polyadenylation site. Genomic coordinates of this collection of almost 1.5 million single-nucleotide-resolution read end sites were extended by 50 nt upstream and downstream, and overlapping intervals were collapsed into a total of 274,330 putative polyadenylation regions. The number of control and triple KD reads ending in each of these regions was counted and, for each gene, the fraction of ONT reads ending in each of its polyadenylation regions was calculated separately for control and triple KD libraries. Genes supported by at least 20 reads in which the contribution of at least one polyA isoform was changed by at least 20 percentage points between triple KD and control were considered differentially polyadenylated. In total, 14,148 genes (4,433 of genomic length over 50 kb) were supported by 20 or more reads, and 247 (231 longer than 50 kb) showed differential polyA site usage.

    Locus-specific L1 quantification

    Raw reads from HEK293 fractionation RNA-seq libraries were aligned to the hg38 genome using bwa aln, and alignments further processed with L1EM65, both with default options. L1EM counts from categories ‘only’, ‘3prunon’ and ‘passive_sense’ were summed. These total read counts were combined with read counts on individual genes (GENCODE v.29 annotation), and DESeq2 differential gene expression analysis was performed together on gene and L1 counts, treating L1 elements as independent genes.

    Reporting summary

    Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

    [ad_2]

    Source link

  • Bone marrow plasma cells require P2RX4 to sense extracellular ATP

    [ad_1]

  • Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741–750 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jarvis, M. F. & Khakh, B. S. ATP-gated P2X cation-channels. Neuropharmacology 56, 208–215 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Borges da Silva, H. et al. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. Nature 559, 264–268 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Burnstock, G. P2X ion channel receptors and inflammation. Purinergic Signal. 12, 59–67 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ishikawa, M. et al. Pannexin 3 functions as an ER Ca(2+) channel, hemichannel and gap junction to promote osteoblast differentiation. J. Cell Biol. 193, 1257–1274 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ishikawa, M. et al. Pannexin 3 and connexin 43 modulate skeletal development through their distinct functions and expression patterns. J. Cell Sci. 129, 1018–1030 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wilmore, J. R., Jones, D. D. & Allman, D. Protocol for improved resolution of plasma cell subpopulations by flow cytometry. Eur. J. Immunol. 47, 1386–1388 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jones, D. D. et al. mTOR has distinct functions in generating versus sustaining humoral immunity. J. Clin. Invest. 126, 4250–4261 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cassese, G. et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171, 1684–1690 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Burnstock, G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64, 1471–1483 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hohenegger, M. et al. Gsalpha-selective G protein antagonists. Proc. Natl Acad. Sci. USA 95, 346–351 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jones, C. A. et al. Functional characterization of the P2X(4) receptor orthologues. Br. J. Pharmacol. 129, 388–394 (2000).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Heng, T. S., Painter, M. W. & The Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091–1094 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tabula Sapiens Consortium. The tabula sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. Science 376, eabl4896 (2022).

    Article 

    Google Scholar
     

  • Hobeika, E. et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl Acad. Sci. USA 103, 13789–13794 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Khalil, A. M., Cambier, J. C. & Shlomchik, M. J. B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science 336, 1178–1181 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ahuja, A., Anderson, S. M., Khalil, A. & Shlomchik, M. J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105, 4802–4807 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yannoutsos, N. et al. A cis element in the recombination activating gene locus regulates gene expression by counteracting a distant silencer. Nat. Immunol. 5, 443–450 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577–1584 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Morris, S. C., Cheek, R. L., Cohen, P. L. & Eisenberg, R. A. Autoantibodies in chronic graft versus host result from cognate T–B interactions. J. Exp. Med. 171, 503–517 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Koshimizu, T. A. et al. Characterization of calcium signaling by purinergic receptor-channels expressed in excitable cells. Mol. Pharmacol. 58, 936–945 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bettigole, S. E. & Glimcher, L. H. Endoplasmic reticulum stress in immunity. Annu. Rev. Immunol. 33, 107–138 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Han, J. et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 15, 481–490 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Puthalakath, H. et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129, 1337–1349 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wilmore, J. R. & Allman, D. Here, there and anywhere? Arguments for and against the physical plasma cell survival niche. J. Immunol. 199, 839–845 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Robinson, M. J. et al. Intrinsically determined turnover underlies broad heterogeneity in plasma-cell lifespan. Immunity 56, 1596–1612 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Benson, M. J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655–3659 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–98 (2004).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Peperzak, V. et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290–297 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nikbakht, N., Migone, T. S., Ward, C. P. & Manser, T. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J. Immunol. 187, 37–46 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. & Mackay, F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203–215 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Suurvali, J., Boudinot, P., Kanellopoulos, J. & Ruutel Boudinot, S. P2X4: a fast and sensitive purinergic receptor. Biomed. J. 40, 245–256 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fujisaki, J. et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474, 216–219 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Glatman Zaretsky, A. et al. T regulatory cells support plasma cell populations in the bone marrow. Cell Rep. 18, 1906–1916 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zinszner, H. et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982–995 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tellier, J. et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat. Immunol. 17, 323–330 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Slifka, M. K., Antia, R., Whitmire, J. K. & Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363–372 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Seckinger, A. et al. Target expression, generation, preclinical activity and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31, 396–410 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748–755 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907–4916 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Woodle, E. S., Tremblay, S. & Driscoll, J. Targeting plasma cells with proteasome inhibitors: principles from primates. J. Am. Soc. Nephrol. 28, 1951–1953 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cheng, Q. et al. Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies. Eur. J. Immunol. 50, 284–291 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ralevic, V. & Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413–492 (1998).

    CAS 
    PubMed 

    Google Scholar
     

  • Iwamoto, T. et al. Pannexin 3 regulates intracellular ATP/cAMP levels and promotes chondrocyte differentiation. J. Biol. Chem. 285, 18948–18958 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for single-cell transcriptomics. Nat. Methods 15, 1053–1058 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • [ad_2]

    Source link